

Articles

Organic Syntheses via Transition-Metal Complexes. 99.¹ Cyclopentadiene Annulation to Enolizable Cyclic Ketones via (1-Alkynyl)carbene Complexes (M = Cr, W)[†]

Rudolf Aumann,* Roland Fröhlich,[‡] Jörg Prigge,[‡] and Oliver Meyer[‡]

*Organisch-Chemisches Institut der Universität Münster, Corrensstrasse 40,
D-48149 Münster, Germany*

Received December 22, 1998

The procedure for a metal-mediated cyclopentadiene annelation to enolizable cycloalkanones is described. Its key step is based on the cyclization of a 1-metalla-1,3,5-hexatriene intermediate, which is generated from the 1-metalla-1,5-hexadien-3-yne ($\text{CO}_5\text{M}=\text{C}(\text{OEt})\text{C}\equiv\text{CC}(\sim)=\text{CH}(\sim)$ (**3**; M = Cr, W) precursor. Addition of secondary amines **4a,b** to [2-(1-cyclopentenyl)ethynyl]carbene complexes **3a,b** (M = W, Cr) affords the 4-amino-1-metalla-1,3,5-hexatrienes (*3E*)-**5a–d**, which cyclize spontaneously to the $\eta^1(C,M)$ -cyclopentadiene complexes **6a–d**. The ring closure is highly stereoselective and involves an *anti* addition (!) of the M=C bond to the terminal C=C bond of the 1-metalla-1,3,5-hexatriene unit. Ligand displacement from compound **6a** is achieved by protonation to give an iminium salt **7a**. Addition of aniline to compounds **3a,b** yields 4-(NH-amino)-1-metalla-1,3,5-hexatrienes (*3Z*)-**10a,b**, which subsequently cyclize to cyclopentenimine(*N,M*) complexes *syn*-**11a,b** and *anti*-**11a,b** and finally afford the cyclopentenimine **12** by oxidative ligand disengagement. Addition of secondary phosphanes **13a,b** to compound **3a** produces a mixture of the isomeric cyclopentadiene(*P,W*)-tungsten complexes *anti*-**14a,b**, *anti*-**15a,b**, and *anti*-**16b**. X-ray structure analyses are reported of compounds (*3E*)-**5a**, **6c**, *anti*-**11a**, *anti*-**16b**, and *anti*-**17a**.

(1-Alkynyl)carbene complexes ($\text{CO}_5\text{M}=\text{C}(\text{OEt})\text{C}\equiv\text{CR}$ (M = W, Cr) have been applied as stoichiometric reagents in a number of high-yield transformations of potential usefulness to organic synthesis.² It has been shown recently that cyclopentadienes can be generated in a [3 + 2] fashion from reaction of (1-alkynyl)carbene complexes with cycloalkenylamines ($\sim\text{CH}=\text{C}(\sim)\text{NR}_2$) in solvents such as dichloromethane. 6-Amino-1-metalla-1,3,5-hexatrienes ($\text{CO}_5\text{M}=\text{C}(\text{OEt})\text{CH}=\text{C}(\text{Ph})\text{C}(\sim)=\text{C}(\sim)(\text{NR}_2)$ (M = W, Cr) were found to be key intermediates in these transformations (=“alkene route to cyclopentadienes”).³ An alternate route to the formation of cyclopentadienes by [3 + 2] cycloaddition is based upon the reaction of the (2-amino-1-alkenyl)carbene–chromium complexes (=4-amino-1-chroma-1,3-butadienes) ($\text{CO}_5\text{Cr}=\text{C}(\text{OEt})\text{CH}=\text{C}(\text{R}')\text{NR}_2$ with alkynes $\text{RC}\equiv\text{CH}$, and the 6-amino-1-chroma-1,3,5-hexatrienes ($\text{CO}_5\text{Cr}=\text{C}(\text{OEt})\text{CH}=\text{C}(\text{R}')\text{NR}_2$ (generated by insertion of the C=C into the Cr=C bond) are thought to be key intermediates (=“alkyne route to cyclopentadienes”).^{2a} A strong driving force for the cyclization of 1-metalla-1,3,5-hexatrienes to cyclopentadienes is provided by amino substituents and not only 6-amino- (vide supra) but also 2-amino- and 4-amino substituents were found to enhance this reaction. Examples of the latter type comprise cyclization both of the 2-amino-1-tungsta-1,3,5-hexatriene ($\text{CO}_5\text{W}=\text{C}(\text{NEt}_2)\text{C}(\text{Me})=\text{C}(\text{OEt})\text{CH}=\text{CHPh}$ (generated by insertion of the 1-aminoalkyne $\text{Et}_2\text{NC}\equiv\text{CMe}$ into the W=C bond of the 1-tungsta-1,3-butadiene ($\text{CO}_5\text{W}=\text{C}(\text{OEt})\text{CH}=\text{CHPh}$)^{4a} as well as the 4-amino-1-tungsta-1,3,5-hexatriene ($\text{CO}_5\text{W}=\text{C}(\text{OEt})\text{CH}=\text{C}(\text{NEt}_2)\text{C}(\text{Me})=\text{CHPh}$ (generated by insertion of the 1-aminoalkyne $\text{Et}_2\text{NC}\equiv\text{CMe}$ into the C=C bond of the 1-tungsta-1,3-butadiene ($\text{CO}_5\text{W}=\text{C}(\text{OEt})\text{CH}=\text{CHPh}$)^{4b} to η^1 -cyclopentadiene complexes under very mild conditions at 20 °C.^{4b} It should be noted that, to date, experimental proof of cyclopentadiene formation by cyclization of 1-metalla-1,3,5-hexatrienes is limited to the aforementioned 2-amino-, 4-amino, and 6-amino derivatives.

We now wish to report on a newly developed metal-mediated cyclopentadiene annelation to enolizable cy-

[†] Dedicated to Prof. H. Werner on the occasion of his 65th birthday.
[‡] X-ray structure analyses.


(1) For part 98 of this series see: Aumann, R.; Kössmeier, M.; Jäntti, A. *Synlett* **1998**, 1120.

(2) For recent reviews see: (a) de Meijere, A. *Pure Appl. Chem.* **1996**, 68, 61. (b) Aumann, R.; Nienaber, H. *Adv. Organomet. Chem.* **1997**, 41, 161.


(3) (a) Aumann, R.; Roths, K.; Grehl, M. *Synlett* **1993**, 669. (b) Aumann, R.; Kössmeier, M.; Roths, K.; Fröhlich, R. *Synlett* **1994**, 1041. (c) Meyer, A. G.; Aumann, R. *Synlett* **1995**, 1011. (d) Aumann, R.; Roths, K.; Jasper, B.; Fröhlich, R. *Organometallics* **1996**, 15, 1257. (e) Aumann, R.; Kössmeier, M.; Zippel, F. *Synlett* **1997**, 621. (f) Aumann, R.; Meyer, A. G.; Fröhlich, R. *Organometallics* **1996**, 15, 5018.

(4) (a) Aumann, R.; Heinen, H.; Hinterding, P.; Sträter, N.; Krebs, B. *Chem. Ber.* **1991**, 124, 1229. (b) Aumann, R.; Heinen, H.; Dartmann, M.; Krebs, B. *Chem. Ber.* **1991**, 124, 2343.

Scheme 1. Principle of the Metal-Mediated Cyclopentadiene Annulation to Enolizable Cycloalkanones in Overall [2 + 2 + 1] Fashion



Scheme 2. 1-Metalla-1,5-hexadien-3-ynes 3 from Cycloalkanones



1,2	a	3	a	M	[%] ^a
a	CH ₂	a	CH ₂	W	84
b	CH ₂ CH ₂	b	CH ₂	Cr	89
c	CH ₂ CH ₂ CH ₂	c	CH ₂ CH ₂	W	78
d		d	CH ₂ CH ₂ CH ₂	W	72

^a Isolated chemical yields.

cycloalkanones involving the successive addition of acetylene, carbon monoxide, an alkyl group, and a protic nucleophile NuH (Scheme 1). The key step of this reaction sequence is based on the cyclization of a 1-metalla-1,3,5-hexatriene intermediate, which is generated by addition of a protic nucleophile NuH to the C≡C bond of a 1-metalla-1,5-hexadien-3-yne precursor $(CO)_5M=C(OEt)C\equiv CC(\sim)=CH(\sim)$ ($M = Cr, W$). It will be demonstrated that amino as well as phosphanyl substituents at the 4-position of the 1-metalla-1,3,5-hexatriene are well-suited to trigger the π -cyclization of such compounds under mild conditions.

[2-(1-Alkenyl)ethynyl]carbene Complexes (=1-Metalla-1,5-hexadien-3-ynes)


The first part of our investigation took aim at the preparation of 1-metalla-1,5-hexadien-3-ynes $(CO)_5M=C(OEt)C\equiv CC(\sim)=CH(\sim)$ (**3a–d**; $M = Cr, W$) from cycloalkenones **1a–c**. Our procedure is straightforward and involves formation of 1-ethynylcycloalkenes **2a–c** from ketones **1a–c** and acetylene via carbinoles.⁵ Compounds **2** are finally transformed into the (1-alkynyl)-carbene complexes **3** by the Fischer route (Scheme 2).⁶

Reaction of (1-alkynyl)carbene complexes $(CO)_5M=C(OEt)C\equiv CR$ ($M = Cr, W; R = aryl, alkyl$) with secondary and primary amines, respectively, was previously shown to yield 4-amino-1-metalla-1,3-dienes of opposite configurations, *3E* and *3Z*, respectively, with

(5) Brandsma, L. *Preparative Acetylenic Chemistry*, 2nd ed.; Elsevier: Amsterdam, 1998; p 204.

(6) (a) Fischer, E. O.; Kreissl, F. R. *J. Organomet. Chem.* **1972**, *35*, C47. (b) Fischer, E. O.; Kalder, H. J. *J. Organomet. Chem.* **1977**, *131*, 57. (c) Fischer, E. O.; Schubert, U.; Kleine, W.; Fischer, H. *Inorg. Synth.* **1979**, *19*, 164.

Scheme 3. Generation of (3*E*)-4-Amino-1-metalla-1,3,5-trienes 5 and η^1 -Cyclopentadiene Complexes 6 by Addition of Secondary Amines to (1-Alkynyl)carbene Complexes 3a,b^a



1,2	a	3	a	M	[%] ^a
a	CH ₂	a	CH ₂	W	84
b	CH ₂ CH ₂	b	CH ₂	Cr	89
c	CH ₂ CH ₂ CH ₂	c	CH ₂ CH ₂	W	78
d		d	CH ₂ CH ₂ CH ₂	W	72

^a Isolated chemical yields.

high stereoselectivity.^{2b,7} On the basis of these results, it could be predicted that (3*E*)-4-amino-1-metallatrienes **5** would be generated by addition of secondary amines to [2-(1-cyclopentenyl)ethynyl]carbene complexes of chromium and tungsten (**3a,b**; Scheme 3), and (3*Z*)-4-amino-1-metallatrienes **10** of opposite stereochemistry by addition of primary arylamines (Scheme 7). We subsequently present details of the formation of compounds **3** and **10**, as well as its cyclization reactions to cyclopentadiene complexes and cyclopentenimine complexes, respectively.

(3*E*)-4-Amino-1-metalla-1,3,5-hexatrienes 5 and η^1 -Aminocyclopentadiene Complexes 6

(3*E*)-4-Amino-1-metalla-1,3,5-hexatrienes (*3E*)-**5a–d** are obtained as yellow crystals, if secondary amines **4a,b** [HNM_2 and (2*S*)-(methoxymethyl)pyrrolidine] are added to [2-(1-cyclopentenyl)ethynyl]carbene complexes **3a,b** ($M = W, Cr$) in diethyl ether at 0 °C (Scheme 3). The reaction is fast, and the point of equivalency is visually recognized by a color change from dark brown to bright yellow. If isolation of compounds (*3E*)-**5** is intended, solvent must be removed immediately, since compounds (*3E*)-**5a–d** are stable in the solid state but undergo ring closure in solution at ambient temperature to give the zwitterionic η^1 -cyclopentadiene complexes **6a–d** (vide infra). Recrystallization of compounds **5** from diethyl ether may be achieved with minor loss, if carried out quickly at low temperature.

The ¹³C NMR chemical shifts of the $M=C$ group (e.g. tungsten complex (*3E*)-**5a**, δ 268.5; chromium complex (*3E*)-**5b**, δ 287.1) as well as of the C6–N unit (e.g. (*3E*)-**5a**, δ 157.2; (*3E*)-**5b**, 154.2) of compounds (*3E*)-**5** are typically observed with planar and highly polarized enamino carbene complexes $(OC)_5M=C(OEt)CH=C-$

(7) (a) Duetsch, M.; Stein, F.; Lackmann, R.; Pohl, E.; Herbst-Irmer, R.; de Meijere, A. *Chem. Ber.* **1992**, *125*, 2051. (b) Aumann, R.; Hinterding, P. *Chem. Ber.* **1993**, *126*, 421.





Figure 1. Molecular structure of 4-amino-tungsta-1,3,5-hexatriene species (*3E*)-5a. Selected bond lengths (Å) and angles (deg): W–C4 = 2.281(6), C4–O3 = 1.336(8), C4–C5 = 1.391(9), C5–C6 = 1.392(9), C6–N7 = 1.346(9), C6–C60 = 1.490(9), C60–C61 = 1.443(11), C60–C64 = 1.373(12); W–C4–O3 = 127.7(5), W–C4–C5 = 119.2(4), O3–C4–C5 = 113.1(6), C4–C5–C6 = 129.1(6), C5–C6–N7 = 120.9(6), C5–C6–C60 = 123.4(6), C60–C6–N7 = 115.7(6), C6–C60–C61 = 123.2(7), C6–C60–C64 = 124.0(7), C61–C60–C64 = 112.7(7), C60–C61–C62 = 106.1(7), C60–C64–C63 = 108.6(8), C10–W–C4–C5 = 136.7(6).

(NR₂)~ of *3E* configuration⁷ in a range clearly distinct from (nonplanar) *torquo*-carbiminium carbonylmetallates $-(OC_5M-C(OEt)=CHC(=N^+R_2))$.⁸ The (planar) enamine structure of compounds (*E*)-5 is confirmed in the X-ray structure analysis of compound (*3E*)-5a by the dihedral angles C4–C5–C6–N7 = -173.8(8)°, C5–C6–N7–C8 = -174.6(9)°, and W–C4–C5–C6 = -176.7(6)° as well as by the pattern of nonalternating bond distances C4–C5 = 1.391(9) Å, C5–C6 = 1.392(9) Å, and C6–N7 = 1.346(9) Å within the ligand backbone, which indicates strong π -delocalization (Figure 1).

The methylene protons of (*3E*)-5a are diastereotopic due to chirality induced by distortion of the 1-cyclopentenyl group from planarity by C5–C6–C60–C64 = 86.3–(10)° (Figure 1). A sharp set of clearly separated signals is observed in the ¹H NMR spectra of compound (*3E*)-5a below -40 °C (CDCl₃, 600 MHz), but line broadening caused by rapid exchange processes is found above this temperature. Two degenerate reactions (Scheme 4; (1) and (2), respectively) can be distinguished from different activation enthalpies at the coalescence temperatures. ΔG^\ddagger = ca. 60 kJ/mol was found for the interconversion (1) of structures (*3E*)-5a and (*3E*)-5a' (leading to an exchange of the magnetic environments of the N–CH₃ groups); ΔG^\ddagger = ca. 51 kJ/mol was determined for the interconversion (2) of structures (*3E*)-5a and (*3E*)-5a'' (involving an exchange of the magnetic environments of the diastereotopic methylene protons OCH₂ as well as 3'-H₂, 4'-H₂, and 5'-H₂ of the cyclopentene ring) (Scheme 4).

Introduction of a chiral amine substituent into the 1-metalla-1,3,5-hexatriene (*3E*)-5 leads to generation of diastereomers. Four diastereomers were found to be present in the solution of (*3E*)-5c, in which (2*S*)-(methoxymethyl)pyrrolidine (**4b**) is attached to the metallatriene unit. These are rapidly interconverting on the NMR time scale, but two sets of signals in a ratio of ca. 1:2 can be distinguished in the ¹H NMR spectrum (CDCl₃, 600 MHz) at -10 °C for the stereoisomers (*3E*)-


Scheme 4. Degenerate Rearrangements, (1) and (2), Respectively, of Metallatriene (*3E*)-5a^a



Interconversion	H atoms observed	Δv [Hz] in CDCl ₃ , T _c [K] 600 MHz, 213 K	ΔG^\ddagger [kJ/mol]
(<i>3E</i>)-5a and (<i>3E</i>)-5a'	N(CH ₃) ₂	22	283 ca. 60
(<i>3E</i>)-5a and (<i>3E</i>)-5a''	OCH ₂	28	240 ca. 52
(<i>3E</i>)-5a and (<i>3E</i>)-5a''	3'-H ₂	36	243 ca. 50
(<i>3E</i>)-5a and (<i>3E</i>)-5a''	4'-H ₂	56	253 ca. 51
(<i>3E</i>)-5a and (<i>3E</i>)-5a''	5'-H ₂	178	270 ca. 52

^a ΔG^\ddagger values are estimated from NMR measurements at different temperatures.

Chart 1. Alternate (Experimentally Unobserved) Coordination Modes of Cyclopentadiene Complexes 6



5c and (*3E*)-5c' resulting from different configurations of the C3–N bond. Two more sets of signals, which appear at -40 °C, are attributed to right- and left-handed spiral structures, respectively, of the 1-metallaheptatriene (*3E*)-5c (analogous to the structures (*3E*)-5a and (*3E*)-5a'' in Scheme 4). 4-Amino-1-metallaheptatrienes (*3E*)-5 are stable in the solid state but undergo smooth rearrangement in solution within a few hours at ambient temperature to zwitterionic η^1 -cyclopentadiene complexes **6**. The reaction can be monitored by NMR spectra.

It should be noted that a zwitterionic η^1 coordination of the bridgehead α -carbon atom of the aminocyclopentadiene unit to the W(CO)₅ group (Scheme 3) is favored over the coordination mode **B** of the nitrogen atom of the NR₂ group or a η^2 coordination modes **C** and **D**, respectively, of a C=C bond (Chart 1).

The η^1 coordination^{4b} in cyclopentadiene complexes **6** is indicated in the ¹³C NMR spectrum by a high-field shift of the M–C unit (**6c**, W–C δ 50.6; **6d**, Cr–C δ 54.3) and a low-field shift of the C=N unit (**6c**, δ 190.3; **6d**, δ 187.8). The carbiminium carbonylmetallate structure is further documented in the X-ray structure analysis of compound **6c** by the long distance of the W–C single bond, W1–C1 = 2.43(2) Å, and the short distance C8–N9 = 1.37(3) Å of the C–N double bond (Figure 2).⁹

The ring closure of the 4-amino-1-metalla-1,3,5-hexatriene (*3E*)-5c to the η^1 -cyclopentadiene complex

(9) Structural data for a vinylgous carbiminium carbonyltungstate are reported in ref 4b.






Figure 2. Molecular structure of the dihydropentalene carbiminium carbonylmetalate **6c**. Selected bond lengths (\AA) and angles (deg): W1–C1 = 2.43(2), C1–C2 = 1.59(2), C1–C5 = 1.55(3), C1–C8 = 1.37(3), C2–C3 = 1.51(4), C3–C4 = 1.37(4), C4–C5 = 1.58(3), C5–C6 = 1.54(3), C6–O = 1.32(3), C6–C7 = 1.33(3), C7–C8 = 1.50(2), C8–N9 = 1.37(3), N9–C10 = 1.48(2); W–C1–C2 = 116(2), W–C1–C8 = 106.4(12), W–C5–C1 = 108.7(13), C2–C1–C5 = 102(2), C2–C1–C8 = 117(2), C5–C1–C8 = 105(2), C1–C8–N9 = 128(2).

Scheme 5. Cyclization of 1-Metallatrienes by *anti* Addition of the M=C Bond to the 5,6-C=C Bond



($2''S,3aR,6aS$)-**6c** involves an *anti* addition of the M=C bond to the terminal C=C bond (Scheme 5). This stereochemical course is not restricted to the specific geometrical requirements of the bicyclo[3.3.0]octene ring skeleton; it was previously observed also with monocyclic systems.^{4b} An *anti*-addition mode for this ring closure is quite unexpected, considering the fact that metallacyclohexenes or $(\text{CO})_4\text{M}$ chelate complexes would normally be anticipated as intermediates. On the basis of the reasonable assumption that the overall reaction is intramolecular, it can be stated that neither a 1-metallacyclohexa-2,4-diene nor a cyclic $(\text{CO})_4\text{W}$ complex ($= (5,6\text{-}\eta)$ -1-metalla-1,3,5-hexatriene) would be an intermediate en route to the cyclopentadiene complex, since either of these structures should necessarily result in *syn* addition of the M=C bond to the terminal C=C bond. To meet the stereochemical requirements for the ring closure, it is suggested that the zwitterionic species **F** is formed initially, from which the cyclopentadiene complex ($2''S,3aR,6aS$)-**6c** is generated by migration of the $\text{W}(\text{CO})_5$ unit, possibly through the intermediate **G**. The stereocontrol of the reaction is based on the assumption that formation of an *exo*- $\text{W}(\text{CO})_5$ group in the zwitterion **F** should be kinetically strongly favored over formation of the *endo* derivative **E**. Moreover, the

Scheme 6. Ligand Displacement from η^1 -Cyclopentadiene Complexes **6 by Protonation**



reaction path outlined in Scheme 6 does not imply an intermediate disengagement of a carbonyl ligand from the $\text{W}(\text{CO})_5$ group, in line with the exceedingly mild reaction conditions of 20 °C required for the π -cyclization to proceed. Chelation of a pentacarbonyl-1-tungsta-1,3,5-hexatriene by elimination of carbon monoxide to a ($5,6\text{-}\eta$)-tetracarbonyl-1-tungsta-1,3,5-hexatriene (characterized by an X-ray structure analysis)^{3e} was indeed observed at temperatures above 90 °C.


Even though facile ligand elimination is indicated in the mass spectrum of compound **6a** by the base peak *m/e* 193 (100%) and the strong fragment peak *m/e* 165 (90%) resulting from elimination of ethylene, generation of cyclopentadiene **8a** from complex **6a** could not, to date, be achieved on a preparative scale, supposedly due to the low stability of compound **8a** on one side and the high stability of complex **6a** on the other side. Compounds **6a–d** do not exhibit the reactivity expected of an olefin π -complex but rather that of a σ -complex. Thus, ligand displacement from compound **6a** is not achieved, e.g., with pyridine at 70 °C. Extension of the reaction time to 5 h at 70 °C results in partial decomposition of compound **6a** and production of cyclopentenone **9a** (possibly by elimination of ethylene?) and $\text{W}(\text{CO})_6$. On the other hand, addition of HBF_4 in diethyl ether to compound **6a** yields the iminium salt **7a** in a smooth reaction together with $\text{W}(\text{CO})_6$. Addition of 10% $\text{KOH}/90\%$ H_2O to compound **7a** does not produce the cyclopentadiene **8a** but the cyclopentenone **9a** instead (Scheme 6).

(Z)-4-(NH-Amino)-1-metalla-1,3,5-hexatrienes **10, Cyclopentenimine Complexes **11**, and Cyclopentenimine **12****


Addition of primary arylamines ArNH_2 to a (1-alkynyl)carbene complex, e.g. $(\text{CO})_5\text{M}=\text{C}(\text{OEt})\text{C}\equiv\text{CPh}$ ($\text{M} = \text{W}, \text{Cr}$), was shown to afford 4-(aryl amino)-1-metalla-1,3-butadienes $(\text{CO})_5\text{M}=\text{C}(\text{OEt})\text{CH}=\text{C}(\text{NHAr})\text{Ph}$.⁷ The reaction is highly regioselective and also stereoselective with respect to the formation of 3*Z* stereoisomers, which seem to be stabilized by an O...H–N hydrogen bridge.¹⁰ In line with expectation, (3*Z*)-4-NH-amino-1-metalla-1,3,5-trienes (3*Z*)-**10a,b** could be

(10) Aumann, R.; Roths, K.; Kössmeier, M.; Fröhlich, R. *J. Organomet. Chem.* **1998**, 556, 119.

Scheme 7. Generation of 4-(NH-Amino)-1-metalla-1,3,5-hexatrienes (*3Z*)-10** and Its Supposed Course of Cyclization**



Scheme 8. Cyclopentenimine Complexes: Generation, *syn/anti* Isomerization, and Metal Disengagement



generated with high stereoselectivity by addition of aniline to [2-(1-cyclopentenyl)ethynyl]carbene complexes **3a,b** (M = W, Cr) in diethyl ether at 0 °C (Scheme 7). Though *3Z* stereoisomers are isolated as the only products, it could be demonstrated by spin saturation transfer NMR techniques that *3E* stereoisomers will be present in solution, although only in small equilibrium concentrations.¹⁰

4-(NH-Amino)-1-metalla-1,3,5-hexatrienes (*3Z*)-**10** undergo clean cyclization in solution at 50 °C within 4 h to give a mixture of the cyclopentenimine complexes *syn*-**11** and *anti*-**11** (Scheme 8). The products could be separated by column chromatography on silica gel, and it was demonstrated by NMR spectra that the compounds *anti*-**11a,b** are generated from the compounds *syn*-**11a,b** at 50 °C. Cyclization of 4-(NH-amino)-1-metalla-1,3,5-hexatrienes (*3Z*)-**10a,b** to compounds **11a,b** is assumed to follow the route outlined in Scheme 7. The reaction path suggested is similar to that depicted for the generation of compounds (*3E*)-**5c** in Scheme 5, except that zwitterionic carbiminium metalates **H** are assumed to be unstable and undergo proton transfer from the =NH⁺ nitrogen atom to the α-carbon atom. Coordination of the imino function to the M(CO)₅ group appears to stereoselectively produce initially the *syn*-compounds **11** (Scheme 8).

Cyclopentenimine complexes **11** prove quite stable toward attempted ligand displacement with triphenylphosphine or pyridine, but the (metal-free) imine **12** is readily generated from both the chromium complexes




Figure 3. Molecular structure of the imine complex *anti*-**11a**. Selected bond lengths (Å) and angles (deg): W–N12 = 2.276(3), N12–C10 = 1.296(5), N12–C120 = 1.452(5), C10–C9 = 1.528(5), C9–C8 = 1.547(6), C9–C5 = 1.559(5), C8–C7 = 1.526(6), C7–C6 = 1.528(6), C6–C5 = 1.520(6), C5–C4 = 1.503(5), C4–C11 = 1.348(5), C4–O3 = 1.327(5), C11–C10 = 1.434(5); W–N12–C10 = 128.3(2), W–N12–C120 = 114.4(2), C120–N12–C10 = 117.1(3), N12–C10–C9 = 126.0(3), N12–C10–C11 = 125.0(3), C11–C10–C9 = 109.1(3), C10–C9–C8 = 113.2(3), C10–C9–C5 = 104.3(3), C5–C9–C8 = 104.2(3), C9–C8–C7 = 105.4(3), C8–C7–C6 = 102.4(4), C7–C6–C5 = 103.6(3), C6–C5–C4 = 112.8(3), C6–C5–C9 = 106.7(3), C9–C5–C4 = 102.7(3), C5–C4–O3 = 115.7(3), C5–C4–C11 = 114.1(3), O3–C4–C11 = 130.2(4), C4–C11–C10 = 109.4(3).

syn-**11b** and *anti*-**11b** (but not from the corresponding tungsten complexes) by chromatography on silica gel in the presence of air.



The structures of compounds **11** and **12** are based on spectroscopic evidence, as well as on an X-ray structure analysis of *anti*-**11a** (Figure 3).

(*3E*)-4-Phosphanyl-1-metalla-1,3,5-hexatrienes and Phosphanyl-cyclopentadiene Complexes

Addition of secondary phosphanes to the (1-alkynyl)-carbene complexes (CO)₅M=C(OEt)C≡CPh (M = W, Cr) was previously shown to afford the (*3E*)-4-phosphanyl-1-metalla-1,3-butadienes (CO)₅M=C(OEt)CH=C(PR₂)-Ph, which were isolated and characterized by X-ray structure analyses.¹¹ Reaction of the tungsten compound **3a** with secondary phosphanes **13a,b** was found to be fast even at 0 °C and yielded mixtures of phosphanyl-cyclopentadiene complexes **anti**-**14–16** (Schemes 9 and 10), which are coordinated through the phosphorus atom. Reaction intermediates, e.g. compounds **I** and **J** (Scheme 9) could not be detected in this case.¹¹

The overall yield of phosphanyl-cyclopentadiene complexes is high, but the relative amount of isomers *anti*-**14–16** was found to depend on the details of the preparation, since these compounds are interconverted by 1,5-hydrogen shifts as outlined in Scheme 10.

The tungsten compounds *anti*-**14a,b**, *anti*-**15a,b**, and *anti*-**16b** were separated by chromatography on silica gel, under which conditions compounds *anti*-**17a,b** are generated in small amounts by hydrolysis of the enol ether unit. The structures of the phosphanyl compounds could be easily derived from the NMR spectra. The *anti* configuration is assigned on the basis of a low-field shift

Scheme 9. Phosphanylcylopentadiene Complexes**Scheme 10. Phosphanylcylopentadiene Complexes: Isomerization by 1,5-H Shifts and Hydrolysis**

observed for the =CH signal due to the anisotropic influence of the W(CO)₅ group and could also be confirmed by X-ray structure analyses of *anti*-16b and *anti*-17a (Figures 4 and 5). Compounds with a *syn* configuration were not detected in the case of phosphanylcylopentadiene complexes, nor was any indication found for a possible coordination mode of one (or two) carbon atoms.

Experimental Section

All operations were carried out under an atmosphere of dry argon. All solvents were dried and distilled prior to use. ¹H and ¹³C NMR spectra were routinely recorded on Bruker ARX 300 and AM 360 instruments. IR spectra were recorded on a Biorad Digilab Division FTS-45 FT-IR spectrophotometer. ¹J(H,C)–²J(H,C)–³J(H,C) decoupling experiments were performed on a Varian 600 instrument. Elemental analyses were determined on a Perkin-Elmer 240 elemental analyzer. Analytical TLC plates, Merck DC-Alufolien Kieselgel 60_{F240}, were viewed by UV light (254 nm) and stained by a 5% aqueous




Figure 4. Molecular structure of the dihydropentalene phosphine complex *anti*-16b. Selected bond lengths (Å) and angles (deg): W–P = 2.5604(10), P–C₃₁ = 1.858(4), P–C₄₁ = 1.846(4), P–C₆ = 1.812(4), C₆–C₇ = 1.348(5), C₇–C₈ = 1.491(6), C₇–C₁₁ = 1.458(6), C₈–C₉ = 1.533(6), C₉–C₁₀ = 1.517(7), C₁₀–C₁₁ = 1.514(6), C₁₁–C₄ = 1.324(6), C₄–O₃ = 1.354(5), C₄–C₅ = 1.504(5), C₅–C₆ = 1.516(5); W–P–C₃₁ = 114.51(13), W–P–C₄₁ = 114.80(12), W–P–C₆ = 115.22(13), C₃₁–P–C₄₁ = 103.26(17), C₃₁–W–C₆ = 103.47(17), C₄₁–P–C₆ = 104.08(18), P–C₆–C₅ = 122.3(3), P–C₆–C₇ = 130.8(3), C₅–C₆–C₇ = 106.9(3), C₆–C₇–C₈ = 139.3(4), C₆–C₇–C₁₁ = 111.2(4), C₁₁–C₇–C₈ = 109.5(4), C₇–C₈–C₉ = 105.5(4), C₈–C₉–C₁₀ = 108.5(4), C₉–C₁₀–C₁₁ = 104.6(4), C₁₀–C₁₁–C₇ = 110.0(4), C₁₀–C₁₁–C₄ = 141.3(4), C₇–C₁₁–C₄ = 108.7(4), C₁₁–C₄–O₃ = 134.0(4), C₁₁–C₄–C₅ = 109.8(4), O₃–C₄–C₅ = 116.2(4), C₄–C₅–C₆ = 103.4(3).




Figure 5. Molecular structure of the dihydropentalene phosphine complex *anti*-17a. Selected bond lengths (Å) and angles (deg): W–P = 2.6086(11), P–C₆ = 1.887(4), P–C₇ = 1.907(4), P–C₈ = 1.852(4), C₈–C₉ = 1.547(5), C₉–C₁₀ = 1.519(6), C₉–C₁₃ = 1.543(6), C₁₀–C₁₁ = 1.523(7), C₁₁–C₁₂ = 1.511(8), C₁₂–C₁₃ = 1.535(7), C₁₃–C₁₄ = 1.519(6), C₁₄–O₁₄ = 1.215(5), C₁₄–C₁₅ = 1.463(6), C₈–C₁₅ = 1.328(6); W–P–C₆ = 112.5(2), W–P–C₇ = 116.58(14), W–P–C₈ = 110.08(13), C₆–P–C₇ = 110.1(2), C₆–P–C₈ = 106.8(2), C₇–P–C₈ = 99.6(2), P–C₈–C₉ = 130.4(3), P–C₈–C₁₅ = 119.7(3), C₁₅–C₈–C₉ = 109.1(3), C₈–C₉–C₁₀ = 117.4(4), C₈–C₉–C₁₃ = 104.6(3), C₁₃–C₉–C₁₀ = 103.5(4), C₉–C₁₀–C₁₁ = 103.5(4), C₁₀–C₁₁–C₁₂ = 103.3(4), C₁₁–C₁₂–C₁₃ = 103.7(4), C₁₂–C₁₃–C₁₄ = 114.1(4), C₁₂–C₁₃–C₉ = 107.6(4), C₉–C₁₃–C₁₄ = 104.1(4), C₁₃–C₁₄–C₁₅ = 106.8(4), C₁₃–C₁₄–O₁₄ = 125.4(4), O₁₄–C₁₄–C₁₅ = 127.7(4), C₁₄–C₁₅–C₈ = 113.2(4).

acidic ammonium molybdate solution. *R*_f values refer to TLC tests. Chromatographic purifications were performed on Merck Kieselgel 100.

Pentacarbonyl[3-(cyclopent-1-enyl)-1-ethoxyprop-2-yn-1-ylidene]tungsten (3a). W(CO)₅ (3.52 g, 10.00 mmol) is

placed in a 100 mL two-necked flask fitted with an efficient stirrer bar and a 100 mL dropping funnel. After the apparatus has been flushed with argon, 1-ethynylcyclopentene¹² (0.92 g, 10.00 mmol; **2a**) and dry THF (20 mL) is placed into the dropping funnel, and a solution of *n*-BuLi (10.00 mmol, 6.25 mL of a 1.6 M solution in hexane) is added dropwise at 20 °C, while a slow stream of argon is passed through the solution to achieve efficient mixing. After 15 min at 20 °C the solution of (1-ethynylcyclopentenyl)lithium thus generated is added dropwise within 15 min to the W(CO)₆ with rapid stirring. A clear orange solution is obtained, which is very air-sensitive. W(CO)₆ dissolves completely after approximately 80% of the reagent has been added. Evaporation to dryness (20 °C, 20 Torr) gives a bright yellow, very air-sensitive solid, from which the remaining THF is removed at 1 Torr and 20 °C. The residue is dissolved in dry dichloromethane (20 mL), and the solution is cooled to -78 °C. Triethyloxonium tetrafluoroborate (2.85 g, 15.00 mmol) in dry dichloromethane (10 mL) is added at -78 °C with rapid stirring. A dark mixture is formed immediately, which is brought to dryness (20 °C, 20 Torr). The residue is extracted efficiently four times with 50 mL portions of Et₂O to leave a grayish residue of LiBF₄. Crystallization from pentane at -40 °C affords compound **3a** (3.96 g, 84% brown needles, *R*_f = 0.5 in pentane, mp 64 °C). ¹H NMR (C₆D₆): δ 6.20 (1 H, t, 2'-H), 3.97 (2 H, q, OCH₂), 2.32, 1.98 and 1.52 (2 H each, m each, 3'-H₂ to 5'-H), 0.95 (3 H, t, OCH₂CH₃). ¹³C NMR (C₆D₆): δ 284.3 (C_q, W=C), 206.3 and 198.4 [1:4, C_q each, *trans*- and *cis*-CO, W(CO)₅], 148.2 (CH, C2'), 135.6 (C_q, broad, C3), 124.9 (C_q, C1'), 99.8 (C_q, broad, C2'), 76.2 (OCH₂), 36.1, 35.0 and 23.7 (CH₂ each, C3'-C5'), 14.6 (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2142.3 [ν (C≡C)]; 2068.3 (25), 1983.6 (30), 1958.7 (100) [ν (C≡O)]. MS (70 eV; *m/e* ¹⁸⁴W (%)): 472 (40) [M⁺], 414 (50) [M⁺ - 2 CO], 388 (50) [M⁺ - 3 CO], 330 (90) [M⁺ - 5 CO], 302 (90), 273 (100). Anal. Calcd for C₁₅H₁₂NO₆W (472.1): C, 38.16; H, 2.56. Found: C, 38.02; H, 2.69.

Pentacarbonyl[3-(cyclopent-1-enyl)-1-ethoxyprop-2-yn-1-ylidene]chromium (3b). Cr(CO)₆ (2.20 g, 10.00 mmol) is reacted as described above with 1-ethynylcyclopentene¹² (0.92 g, 10.00 mmol; **2a**), *n*-BuLi (10.00 mmol), and triethyloxonium tetrafluoroborate (2.85 g, 15.00 mmol) to give compound **3b** (3.05 g, 89% red-brown crystals, *R*_f = 0.5 in pentane, mp 45 °C). ¹H NMR (C₆D₆): δ 6.18 (1 H, t, 2'-H), 4.06 (2 H, q, OCH₂), 2.31, 2.12 and 1.60 (2 H each, m each, 3'-H₂ to 5'-H), 0.99 (3 H, t, OCH₂CH₃). ¹³C NMR (C₆D₆): δ 314.4 (C_q, Cr=C), 226.3 and 217.2 [1:4, C_q each, *trans*- and *cis*-CO, Cr(CO)₅], 148.0 (CH, C2'), 135.6 (C_q, broad, C3), 124.6 (C_q, C1'), 94.1 (C_q, broad, C2'), 76.1 (OCH₂), 36.1, 35.0, and 23.7 (CH₂ each, C3'-C5'), 14.8 (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2139.9 [ν (C≡C)]; 2061.0 (25), 1987.2 (30), 1962.8 (100) [ν (C≡O)]. MS (70 eV; *m/e* (%)): 340 (20) [M⁺], 284 (20) [M⁺ - 2 CO], 256 (20) [M⁺ - 3 CO], 228 (40) [M⁺ - 4 CO], 200 (100) [M⁺ - 5 CO], 156 (50), 143 (60). Anal. Calcd for C₁₅H₁₂CrNO₆ (340.1): C, 52.95; H, 3.55. Found: C, 52.76; H, 3.41.

Pentacarbonyl[3-(cyclohex-1-enyl)-1-ethoxyprop-2-yn-1-ylidene]tungsten (3c). W(CO)₆ (3.52 g, 10.00 mmol) is reacted as described above with 1-ethynylcyclohexene¹² (1.06 g, 10.00 mmol; **2b**), *n*-BuLi (10.00 mmol), and triethyloxonium tetrafluoroborate (2.85 g, 15.00 mmol) to give compound **3c** (3.79 g, 78%, brown crystals, *R*_f = 0.5 in pentane, mp 67 °C). ¹H NMR (C₆D₆): δ 6.28 (1 H, m, 2'-H), 4.01 (2 H, q, OCH₂), 2.03, 1.70, 1.31, and 1.16 (2 H each, m each, 3'-H₂ to 6'-H), 0.98 (3 H, t, OCH₂CH₃). ¹³C NMR (C₆D₆): δ 283.3 (C_q, W=C),

206.2 and 198.6 [1:4, C_q each, *trans*- and *cis*-CO, W(CO)₅], 145.7 (CH, C2'), 136.5 (C_q, broad, C3), 121.6 (C_q, C1'), 96.9 (C_q, broad, C2'), 76.0 (OCH₂), 28.9, 27.2, 22.3, and 21.3 (CH₂ each, C3'-C6'), 14.7 (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2144.7 [ν (C≡C)]; 2067.6 (25), 1983.2 (30), 1955.2 (100) [ν (C≡O)]. Anal. Calcd for C₁₆H₁₄NO₆W (486.1): C, 39.53; H, 2.90. Found: C, 39.84; H, 3.01.

Pentacarbonyl[3-(cyclohept-1-enyl)-1-ethoxyprop-2-yn-1-ylidene]tungsten (3d). W(CO)₆ (3.52 g, 10.00 mmol) is reacted as described above with 1-ethynylcycloheptene¹² (1.20 g, 10.00 mmol; **2c**), *n*-BuLi (10.00 mmol), and triethyloxonium tetrafluoroborate (2.85 g, 15.00 mmol) to give compound **3d** (3.60 g, 72%, brown crystals, *R*_f = 0.5 in pentane, mp 32 °C). ¹H NMR (C₆D₆): δ 6.62 (1 H, t, ³J = 7 Hz, 2'-H), 4.01 (2 H, q, OCH₂); 2.28, 1.87, 1.49, 1.38, and 1.26 (2 H each, m each, 3'-H₂ to 7'-H), 1.01 (3 H, t, OCH₂CH₃). ¹³C NMR (C₆D₆): δ 286.1 (C_q, W=C), 206.3 and 198.6 [1:4, C_q each, *trans*- and *cis*-CO, W(CO)₅], 151.2 (CH, C2'), 136.5 (C_q, broad, C3), 127.6 (C_q, C1'), 97.3 (C_q, broad, C2'), 75.9 (OCH₂), 34.2, 32.0, 30.8, 26.9, and 26.2 (CH₂ each, C3'-C7'), 14.7 (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2137.2 [ν (C≡C)]; 2067.3 (25), 1983.9 (30), 1955.0 (100) [ν (C≡O)]. MS (70 eV; *m/e* (%)): 500 (10) [M⁺], 444 (20) [M⁺ - 2 CO], 360 (20) [M⁺ - 5 CO], 302 (40), 180 (100). Anal. Calcd for C₁₇H₁₆NO₆W (500.2): C, 40.82; H, 3.22. Found: C, 40.98; H, 3.32.

4-(Cyclopent-1-enyl)-4-(dimethylamino)-2-ethoxy-1,1,1,1-pentacarbonyl-1-tungsta-1,3-butadiene ((3E)-5a) and Pentacarbonyl[1-(dimethylazonia)-3-ethoxy-3a,5,6,6a-tetrahydro-4H-pentalen-6a-yl]tungstate (6a). A solution of 0.5 mmol of dimethylamine (**4a**) in 2 mL of dry diethyl ether is added dropwise with stirring at 0 °C to pentacarbonyl-[3-(cyclopent-1-enyl)-1-ethoxyprop-2-yn-1-ylidene]tungsten (236 mg, 0.5 mmol; **3a**) in 1 mL of dry diethyl ether in a 5 mL screw-top vessel. After a color change from brown to yellow is observed, indicating the point of equivalency, the solution is cooled to -20 °C to give compound **5a** (217 mg, 84%, yellow crystals). Compound (3E)-**5a** (259 mg, 0.5 mmol) in 2 mL of diethyl ether is rearranged completely to compound **6a** at 20 °C and 12 h (pale yellow crystals at -15 °C, 231 mg, 89%, *R*_f = 0.3 in 1:1 pentane/diethyl ether, mp 111 °C). Addition of 2 mL of pentane to the supernatant affords another crop of ca. 30 mg of compound **6a**. The rearrangement of (3E)-**5a** to **6a** is very smooth and can be followed by NMR in CDCl₃. Compound **6a** is conveniently prepared also in a one-pot procedure from compound **3a** directly.


(3E)-5a. ¹H NMR (CDCl₃ at 263 K, freshly prepared sample): δ 6.30 (1 H, s, 3-H), 5.55 (1 H, "s", 2'-H), 4.30 (2 H, m, diastereotopic OCH₂), 3.09 and 3.01 (3 H each, s each, NMe₂), 2.62, 2.51, 2.33, and 2.00 (1:2:1:2 H, m, each 3 CH₂), 1.30 (3 H, t, OCH₂CH₃). ¹³C NMR (CDCl₃ at 263 K): δ 268.5 (C_q, W=C), 204.6 and 199.6 [C_q each, *trans*- and *cis*-CO of W(CO)₅], 157.2 (C_q, C4), 139.0 (C_q, C1'), 130.5 (CH, C2'), 119.3 (CH, C3), 75.7 (OCH₂), 40.8 and 40.5 [N(CH₃)₂], 35.0 (CH₂, C8), 33.2 (CH₂, C6), 22.6 (CH₂, C7), 14.1 (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2056.3 (5), 1943.6 (10), 1923.7 (100) [ν (C≡O)]. MS (70 eV; *m/e* ¹⁸⁴W (%)): 517 (10) [M⁺], 461 (10) [M⁺ - 2 CO], 433 (30) [M⁺ - 3 CO], 405 (10) [M⁺ - 4 CO], 377 (20) [M⁺ - 5 CO], 193 (100). Anal. Calcd for C₁₇H₁₉NO₆W (517.2): C, 39.48; H, 3.70; N, 2.71. Found: C, 39.12; H, 3.57; N, 2.51.

X-ray crystal structure analysis of compound (3E)-**5a**: formula C₁₇H₁₉NO₆W, *M*_r = 517.18, 0.30 × 0.25 × 0.10 mm, *a* = 9.412(1) Å, *b* = 10.337(1) Å, *c* = 11.643(4) Å, α = 112.01(1)°, β = 105.69(1)°, γ = 102.42°, *V* = 945.41(16) Å³, ρ_{calcd} = 1.817 g cm⁻³, μ = 61.40 cm⁻¹, empirical absorption correction via ψ scan data (0.85.7 ≤ *C* ≤ 0.999), *Z* = 2, triclinic, space group P1 (No. 2), λ = 0.710 73 Å, *T* = 223 K, $\omega/2\theta$ scans, 4041 reflections collected ($\pm h$, $-k$, $\pm l$), $(\sin \theta)/\lambda$ = 0.62 Å⁻¹, 3820 independent and 3368 observed reflections [*I* ≥ 2σ(*I*)], 229 refined parameters, *R* = 0.039, *wR* = 0.104, GOF 1.109,

(12) Preparation follows the procedure given in ref 5, but dehydration of the carbinol with phosphoryl chloride/pyridine was carried out at 25 °C, since this reaction was exothermic. Furthermore, the reaction mixture was not hydrolyzed but distilled to give a mixture of 1-ethynylcycloalkene and pyridine as the only volatile products, from which pyridine was extracted by stirring with a small excess of phosphoric acid (ca. 80%) at 20 °C, leaving the 1-ethynylcycloalkene behind in good yields.

maximum (minimum) residual electron density 1.82 (-4.42) e \AA^{-3} , hydrogens calculated and riding.¹³

6a. ^1H NMR (C_6D_6): δ 4.75 (1 H, s, 2-H), 3.82 (1 H, dd, $^3J = 8$ Hz, $^3J = 8$, 3a-H), 3.47 (2 H, m, diastereotopic OCH_2), 2.77 and 2.45 (3 H each, s each, NMe_2), 2.25 and 1.70 (1 H each, m each, diastereotopic 6-H₂), 1.90 and 1.51 (1 H each, m each, diastereotopic 5-H₂), 1.81 and 0.85 (1 H each, m each, diastereotopic 4-H₂), 1.00 (3 H, t, OCH_2CH_3). ^{13}C NMR (C_6D_6): δ 202.9 [C_q, 5 C, W(CO)₅], 193.5 (C_q, C=N), 185.2 (C_q, =C=O), 93.0 (CH, C2), 67.5 (OCH_2), 67.0 (CH, C3a), 50.1 (C_q, C6a), 43.0 and 41.0 [N(CH₃)₂], 38.6 (CH₂, C6), 32.8 (CH₂, C4), 31.9 (CH₂, C5), 14.0 (OCH_2CH_3). IR (diffuse reflection; cm^{-1} (%)): 2050.5 (5), 1943.6 (10), 1892.4 (100) [$\nu(\text{C}\equiv\text{O})$]; 1584.0 (20) [$\nu(\text{C}=\text{N}^+)$]. MS (70 eV; m/e ¹⁸⁴W (%)): 517 (10) [M⁺], 461 (10) [M⁺ - 2 CO], 433 (30) [M⁺ - 3 CO], 405 (10) [M⁺ - 4 CO], 377 (20) [M⁺ - 5 CO], 193 (100), 165 (90). Anal. Calcd for $\text{C}_{17}\text{H}_{19}\text{NO}_6\text{W}$ (517.2): C, 39.48; H, 3.70; N, 2.71. Found: C, 39.32; H, 4.05; N, 2.65.



4-(Cyclopent-1-enyl)-4-(dimethylamino)-2-ethoxy-1,1,1,1-pentacarbonyl-1-chroma-1,3-butadiene ((3E)-5b) and Pentacarbonyl[1-(dimethylazonia)-3-ethoxy-3a,5,6,6a-tetrahydro-4H-pentalen-6a-yl]chromate (6b). Dimethylamine (4a) is reacted with pentacarbonyl[3-(cyclopent-1-enyl)-1-ethoxyprop-2-yn-1-ylidene]chromium (3b) as described above to give a ca. 80% yield of compound (3E)-5b. Compound (3E)-5b (222 mg, 0.5 mmol) in 2 mL of diethyl ether (vide supra) is rearranged at 20 °C and 14 h. Compound 6b is isolated from this solution at -15 °C as a yellow oil, which affords yellow crystals (196 mg, 85%, $R_f = 0.3$ in pentane/diethyl ether 1:1, mp 92 °C) within 1–2 h.

(3E)-5b. ^1H NMR (C_6D_6 , 278 K, freshly prepared sample): δ 6.34 (1 H, s, 3-H), 5.20 (1 H, "s", 2'-H), 4.54 (2 H, m, diastereotopic OCH_2), 2.20 (6 H, s, NMe_2), 2.15, 1.95, 1.70, 1.62 (1:2:1:2 H, m each 3 CH₂), 1.03 (3 H, t, OCH_2CH_3). ^{13}C NMR (CDCl_3 at 263 K): δ 287.1 (C_q, Cr=C), 225.0 and 220.3 [C_q each, trans- and cis-CO of Cr(CO)₅], 154.2 (C_q, C4), 139.8 (C_q, C1), 130.8 (CH, C2'), 118.2 (CH, C3), 73.7 (OCH_2), 39.7 [N(CH₃)₂], 35.6 (CH₂, C8), 33.4 (CH₂, C6), 23.2 (CH₂, C7), 15.4 (OCH_2CH_3). IR (hexane; cm^{-1} (%)): 2044.4 (5), 1959.1 (10), 1915.6 (100) [$\nu(\text{C}\equiv\text{O})$]. Anal. Calcd for $\text{C}_{17}\text{H}_{19}\text{CrNO}_6$ (385.3): C, 52.99; H, 4.97; N, 3.63. Found: C, 52.90; H, 5.12; N, 3.68.

6b. ^1H NMR (C_6D_6): δ 4.90 (1 H, s, 2-H), 3.60 (3 H, m, 3a-H and OCH_2), 2.85 and 2.60 (3 H each, s each, NMe_2), 2.50 and 1.80 (1 H each, m each, diastereotopic 6-H₂), 2.15 and 1.62 (1 H each, m each, diastereotopic 5-H₂), 1.81 and 0.90 (1 H each, m each, diastereotopic 4-H₂), 1.10 (3 H, t, OCH_2CH_3). ^{13}C NMR (C_6D_6): δ 224.6 and 219.5 [C_q each, trans- and cis-CO, Cr(CO)₅], 191.7 (C_q, C=N), 183.6 (C_q, =C=O), 93.5 (CH, C2), 67.6 (OCH_2), 65.0 (CH, C3a), 51.8 (C_q, C6a), 42.2 and 41.3 [N(CH₃)₂], 36.7 (CH₂, C6), 32.3 (CH₂, C4), 31.8 (CH₂, C5), 14.0 (OCH_2CH_3). IR (hexane; cm^{-1} (%)): 2044.4 (5), 1959.6 (10), 1915.6 (100) [$\nu(\text{C}\equiv\text{O})$], 1591.4 (20) [$\nu(\text{C}=\text{N}^+)$]. MS (70 eV; m/e (%)): 385 (10) [M⁺], 301 (10) [M⁺ - 3 CO], 273 (10) [M⁺ - 4 CO], 245 (20) [M⁺ - 5 CO], 193 (10) [ligand], 165 (40) [ligand - C_2H_4], 124 (100). Anal. Calcd for $\text{C}_{17}\text{H}_{19}\text{CrNO}_6$ (385.3): C, 52.99; H, 4.97; N, 3.63. Found: C, 52.95; H, 5.12; N, 3.68.

(13) All data sets were collected with an Enraf-Nonius CAD4/MACH3 diffractometer, equipped with sealed-tube or rotating-anode generators. Programs used: data reduction MolEN, structure solution SHELXS-86, structure refinement SHELXL-93 and SHELXL-97, graphics (with unsystematic numbering schemes) DIAMOND.

4-(Cyclopent-1-enyl)-2-ethoxy-4-[(S)-(methoxymethyl)pyrrolidine]-1,1,1,1-pentacarbonyl-1-tungsta-1,3-butadiene ((3E)-5c) and Pentacarbonyl[3-ethoxy-1-[(2S)-2-(methoxymethyl)pyrrolidinium]-3a,5,6,6a-tetrahydro-4H-pentalen-6a-yl]tungstate ((2''S,3aR,6aS)-6c). (S)-(-)-2-(Methoxymethyl)pyrrolidine (58 mg, 0.5 mmol; 4b) is reacted with pentacarbonyl[3-(cyclopent-1-enyl)-1-ethoxyprop-2-yn-1-ylidene]tungsten (236 mg, 0.5 mmol; 3a) as described above, except that the reaction is performed in 1:1 diethyl ether/pentane, to give compound (3E)-5c (261 mg, 89%, $R_f = 0.6$ in 3:1 pentane/diethyl ether, yellow crystals, mp 85 °C). Compound (3E)-5c (294 mg, 0.5 mmol) in 2 mL of diethyl ether is completely rearranged to compound (2''S,3aR,6aS)-6c at 20 °C and 5 h (yellow crystals obtained at -15 °C, 270 mg, 92%, $R_f = 0.6$ in 3:1 pentane/diethyl ether, mp 85 °C).

(3E)-5c. ^1H NMR (CDCl_3 at 263 K, 600 MHz, freshly prepared sample, shifts of stereoisomer (3E)-5c resulting from hindered rotation of the C4-N bond in brackets): δ 6.44 [6.27] (1 H, s, 3-H), 5.61 [5.52] (1 H, "s", 2'-H), 4.40 [4.38] (2 H, m, diastereotopic 2-OCH₂), 4.06 [3.66] (1 H, t, NCH), 3.60–3.02 [3.60–3.02] (4 H, m, diastereotopic 2''-CH₂O), 3.27 [3.24] (3 H, OCH_3), 2.6–2.4 [2.6–2.4] (4 H, 3''-H₂ and 4''-H₂), 2.44 [2.40] and 2.12–1.84 [2.12–1.84] (2:4 H, m each 3'-H₂, 4'-H₂, and 5'-H₂), 1.36 [1.34] (3 H, t, OCH_2CH_3). ^{13}C NMR (CDCl_3 at 263 K): δ 267.8 [265.8] (C_q, W=C), 204.3 [204.2] and 199.7 [199.6] [C_q each, trans- and cis-CO of W(CO)₅], 153.4 (C_q dynamically broadened, C4), 140.3 [138.5] (C_q broad, C1'), 129.7 [128.2] (CH broad, C2'), 120.6 [120.6] (CH broad, C3), 76.1 [76.0] (2-OCH₂), 73.0 [70.0] (2''-CH₂O), 59.1 [59.0] (OCH_3), 58.7 [58.7] (NCH), 49.3 [49.0] (NCH₂ broad), 37.0 [35.9] and 22.2 [22.0] (CH₂ each, C3'' and C4''), 34.8 [33.3] (CH₂, C8), 28.5 [27.2] (CH₂, C6), 22.9 [22.8] (CH₂, C7), 15.3 [15.2] (OCH_2CH_3). IR (hexane; cm^{-1} (%)): 2056.0 (15), 1943.6 (10), 1923.6 (100) [$\nu(\text{C}\equiv\text{O})$]. MS (70 eV; m/e ¹⁸⁴W (%)): 587 (10) [M⁺], 531 (10) [M⁺ - 2 CO], 503 (30) [M⁺ - 3 CO], 447 (20) [M⁺ - 5 CO], 263 (100) [ligand], 248 (100). Anal. Calcd for $\text{C}_{21}\text{H}_{25}\text{NO}_7\text{W}$ (587.3): C, 42.95; H, 4.29; N, 2.39. Found: C, 42.89; H, 5.17; N, 2.55.

(2''S,3aR,6aS)-6c. ^1H NMR (C_6D_6): δ 4.95 (1 H, s, 2-H), 3.97 (1 H, m, 2'-H), 3.95 and 3.10 (1 H each, m each, diastereotopic 5'-H₂), 3.90 (1 H, m, 3a-H), 3.55 (2 H, m, diastereotopic 3-OCH₂), 3.10 and 2.95 (1 H each, dd each, diastereotopic 2'-OCH₂), 2.99 (3 H, s, OCH_3), 2.20 and 2.09 (1 H each, m each, diastereotopic 6-H₂), 1.90 and 1.03 (1 H each, m each, diastereotopic 4-H₂), 1.84, 1.72, and 1.50 (2:1:1 H, m each, NCH₂CH₂CH₂), 1.63 and 1.58 (1 H each, m each, diastereotopic 5-H₂), 1.05 (3 H, t, OCH_2CH_3). ^{13}C NMR (C_6D_6): δ 202.3 [C_q, 5 C, W(CO)₅], 190.3 (C_q, C=N⁺), 184.9 (C_q, =C=O), 95.0 (CH, C2), 73.8 (2'-CH₂O), 67.6 (3-OCH₂), 66.7 (CH, C3a), 62.2 (NCH), 59.0 (OCH_3), 51.0 (NCH₂), 50.6 (C_q, C6a), 38.3 (CH₂, C6), 32.6 (CH₂, C4), 31.6 (CH₂, C5), 27.4 and 24.2 (CH₂ each, C3' and C4'), 14.4 (OCH_2CH_3). IR (hexane; cm^{-1} (%)): 2054.1 (10), 1957.2 (10), 1911.6 (100) [$\nu(\text{C}\equiv\text{O})$], 1587.4 [$\nu(\text{C}=\text{N}^+)$]. MS (70 eV; m/e ¹⁸⁴W (%)): 587 (5) [M⁺], 431 (5) [M⁺ - 2 CO], 503 (5) [M⁺ - 3 CO], 447 (20) [M⁺ - 5 CO], 263 (65) [ligand], 248 (100). Anal. Calcd for $\text{C}_{21}\text{H}_{25}\text{NO}_7\text{W}$ (587.3): C, 42.95; H, 4.29; N, 2.39. Found: C, 42.89; H, 4.27; N, 2.55.

X-ray crystal structure analysis of compound (2''S,3aR,6aS)-6c: formula $\text{C}_{21}\text{H}_{25}\text{NO}_7\text{W}$, $M_r = 587.27$, $0.5 \times 0.4 \times 0.1$ mm, $a = 10.613(3)$ Å, $b = 18.328(4)$ Å, $c = 12.273(4)$ Å, $\beta = 105.49$ (2)°, $V = 2300.6(11)$ Å³, $\rho_{\text{calcd}} = 1.696$ g cm⁻³, $\mu = 50.60$ cm⁻¹, empirical absorption correction via ψ scan data ($0.644 \leq C \leq 0.999$), $Z = 4$, monoclinic, space group $P2_1$ (No. 4), $\lambda = 0.710$ 73 Å, $T = 223$ K, $\omega/2\theta$ scans, 4995 reflections collected ($\pm h, +k, +l$), ($\sin \theta/\lambda$) = 0.62 Å⁻¹, 4774 independent and 4113 observed reflections [$I \geq 2\sigma(I)$], 528 refined parameters, $R1 = 0.066$, $wR2 = 0.172$, GOF 1.029, maximum (minimum) residual electron density 4.45 (-2.07) e Å⁻³, Flack parameter 0.00(3), group C17–O18–C19 in molecule I disordered, refined with isotropic thermal parameters and with restraints, hydrogens calculated and riding.¹³

4-(Cyclopent-1-enyl)-2-ethoxy-4-[*(S*)-(methoxymethyl)pyrrolidine-1,1,1,1-pentacarbonyl-1-chroma-1,3-butadiene ((3*E*)-5d) and Pentacarbonyl[3-ethoxy-1-[2-(methoxymethyl)pyrrolidinium]-3a,5,6,6a-tetrahydro-4H-pentalen-6a-yl]chromate ((2''*S,5S*)-6d). (*S*-(-)-2-(Methoxymethyl)pyrrolidine (58 mg, 0.5 mmol; **4b**) is reacted with pentacarbonyl[3-(cyclopent-1-enyl)-1-ethoxyprop-2-yn-1-ylidene]chromium (170 mg, 0.5 mmol; **3b**) as described above to give compound (3*E*)-5d (184 mg, 81%, R_f = 0.6 in 2:1 pentane/diethyl ether, yellow crystals, mp 82 °C). Compound (3*E*)-5d (227 mg, 0.5 mmol) in 2 mL of diethyl ether is completely rearranged at 20 °C and 4 h to compound (2''*S,5S*)-6d (yellow crystals obtained at -15 °C, 195 mg, 86%, R_f = 0.6 in 2:1 pentane/diethyl ether, mp 82 °C).

(3*E*)-5d. ^1H NMR (CDCl_3 at 263 K, 600 MHz, freshly prepared sample, stereoisomer (3*E*)-5d in brackets): δ 6.37 [6.21] (1 H, s, 3-H), 5.59 [5.50] (1 H, "s", 2'-H), 4.60 [4.45] (2 H, m, diastereotopic 2-OCH₂), 4.16 [3.80] (1 H, t, NCH), 3.60–3.02 [3.60–3.02] (4 H, m, diastereotopic 2''-CH₂O), 3.35 [3.29] (3 H, OCH₃), 2.6–2.4 [2.6–2.4] (4 H, 3''-H₂ and 4''-H₂), 2.44 [2.44] and 2.12–1.84 [2.12–1.84] (2:4 H, m each 3''-H₂, 4''-H₂, and 5''-H₂), 1.36 [1.30] (3 H, t, OCH₂CH₃). ^{13}C NMR (CDCl_3 at 263 K): δ 279.8 [274.6] (C_q, Cr=C), 224.4 [224.2] and 219.0 [219.0] (C_q each, *trans*- and *cis*-CO of Cr(CO)₅), 152.3 [152.3] (C_q dynamically broadened, C4), 142.3 [138.7] (C_q broad, C1'), 129.7 [128.2] (CH broad, C2'), 118.4 [118.4] (CH broad, C3), 73.4 [73.1] (2-OCH₂), 73.0 [70.1] (2''-CH₂O), 59.0 [58.6] (OCH₃), 58.5 (NCH), 49.9 [48.9] (NCH₂ broad), 38.0 [36.0] and 22.6 [22.0] (CH₂ each, C3'' and C4''), 35.0 [33.2] (CH₂, C8), 28.3 [27.2] (CH₂, C6), 22.9 [22.6] (CH₂, C7), 15.4 [15.3] (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2056.0 (15), 1943.6 (10), 1923.6 (100) [ν (C=O)]. MS (70 eV; m/e (%)): 455 (10) [M⁺], 399 (10) [M⁺ – 2 CO], 343 (30) [M⁺ – 4 CO], 315 (20) [M⁺ – 5 CO], 263 (100) [ligand], 248 (100). Anal. Calcd for $\text{C}_{21}\text{H}_{25}\text{CrNO}_7$ (455.3): C, 55.38; H, 5.53; N, 3.08. Found: C, 55.04; H, 5.65; N, 3.16.

(2''*S,5S*)-6d. ^1H NMR (C_6D_6): δ 4.95 (1 H, s, 2-H), 3.82 (1 H, m, 2'-H), 3.78 and 3.00 (1 H each, m each, diastereotopic 5'-H₂), 3.70 (1 H, m, 3a-H), 3.65 (2 H, m, diastereotopic 3-OCH₂), 2.92 and 2.81 (1 H each, diastereotopic 2'-CH₂O), 2.85 (3 H, s, OCH₃), 2.10–1.60 (10 H, m, 5 CH₂), 0.90 (3 H, t, OCH₂CH₃). ^{13}C NMR (C_6D_6): δ 224.6 and 219.8 (C_q each, *trans*- and *cis*-CO, W(CO)₅), 187.8 (C_q, C=N⁺), 182.8 (C_q, =C–O), 95.0 (CH, C2), 73.7 (2'-CH₂O), 64.6 (CH, C3a), 62.2 (NCH), 59.0 (OCH₃), 54.3 (C_q, C6a), 51.6 (NCH₂), 36.0 (CH₂, C6), 32.0 (CH₂, C5), 31.0 (CH₂, C5), 27.1 and 24.0 (CH₂ each, C3' and C4'), 14.1 (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2047.2 (10), 1986.2 (10), 1926.4 (100) [ν (C=O)]; 1558.4 [ν (C=N⁺)]. MS (70 eV; m/e 184W (%)): 587 (5) [M⁺], 431 (5) [M⁺ – 2 CO], 503 (5) [M⁺ – 3 CO], 447 (20) [M⁺ – 5CO], 263 (65) [ligand], 248 (100). Anal. Calcd for $\text{C}_{21}\text{H}_{25}\text{CrNO}_7$ (455.3): C, 55.38; H, 5.53; N, 3.08. Found: C, 55.21; H, 5.27; N, 2.95.

1-(Dimethylazonia)-3-ethoxy-3a,5,6,6a-tetrahydro-4H-pentalene Tetrafluoroborate (7a) and 3-(Dimethylamino)-3a,5,6,6a-tetrahydro-4H-pentalen-1-one (9a). Pentacarbonyl[1-(dimethylazonia)-3-ethoxy-3a,5,6,6a-tetrahydro-4H-pentalen-6a-yl]tungstate (259 mg, 0.5 mmol; **6a**) in 5 mL of diethyl ether, water (9 mg, 0.5 mmol), and Et₃OB₄ (95 mg, 0.5 mmol) was stirred until the mixture turned colorless (at 20 °C, 14 h). The crystalline residue of compound **7a** was washed with diethyl ether in order to remove W(CO)₆ and dried in vacuo (125 mg, 89%). Reaction of **7a** with 10% KOH in water affords the colorless ketone **9a**. A 1:1 mixture of compound **6a** and pyridine in C_6D_6 was heated for 5 h at 70 °C to give a 1:1 mixture of compounds **6a** and **9a**.

7a. ^1H NMR (CDCl_3): δ 5.91 (1 H, s, 2-H), 4.32 (2 H, m, diastereotopic OCH₂), 3.59 and 3.41 (1 H each, m each, 3a-H and 6a-H), 3.40 and 3.39 (3 H each, s each, NMe₂), 2.21 and 1.76 (1 H each, m each, diastereotopic 6-H₂), 1.86 and 1.72 (1 H each, m each, diastereotopic 5-H₂), 1.74 and 1.49 (1 H each, m each, diastereotopic 4-H₂), 1.42 (3 H, t, OCH₂CH₃). ^{13}C NMR (CDCl_3): δ 193.7 (C_q, =COEt), 187.6 (C_q, C=N), 98.9 (CH, C2),

70.6 (OCH₂), 49.4 and 42.5 (CH each, C3a and C6a), 45.3 and 43.1 [N(CH₃)₂], 28.9 and 28.4 (CH₂ each, C6 and C4), 24.6 (CH₂, C5), 13.9 (OCH₂CH₃). IR (diffuse reflection; cm⁻¹): 1652.0 and 1584.3 [ν (C=CC=N⁺)]. MS (70 eV; m/e 184W (%)): 517 (10) [M⁺], 461 (10) [M⁺ – 2 CO], 433 (30) [M⁺ – 3 CO], 405 (10) [M⁺ – 4 CO], 377 (20) [M⁺ – 5 CO], 193 (100) [ligand], 165 (90) [193 – C₂H₄]. Anal. Calcd for $\text{C}_{17}\text{H}_{20}\text{BF}_4\text{NO}$ (341.2): C, 59.85; H, 5.91; N, 4.12. Found: C, 59.12; H, 6.10; N, 3.90.

9a. ^1H NMR (CDCl_3): δ 4.86 (1 H, s, 2-H), 3.18 and 2.80 (1 H each, m each, 3a-H and 6a-H), 3.05 and 2.85 (3 H each, s each, NMe₂), 1.94 and 1.60 (1 H each, m each, diastereotopic 6-H₂), 1.76 and 1.57 (1 H each, m each, diastereotopic 5-H₂), 1.54 and 1.40 (1 H each, m each, diastereotopic 4-H₂). ^{13}C NMR (CDCl_3): δ 205.5 (C_q, =C=O), 179.6 (C_q, =CN), 100.2 (CH, C2), 51.4 and 44.1 (CH each, C3a and C6a), 39.5 and 38.5 [N(CH₃)₂], 30.3 and 29.3 (CH₂ each, C4 and C6), 24.2 (CH₂, C5). IR (diffuse reflection; cm⁻¹): 1576 [ν (C=O)]. MS (70 eV; m/e (%)): 165 (40) [M⁺], 137 (20), 124 (100). Anal. Calcd for $\text{C}_{10}\text{H}_{15}\text{NO}$ (165.2): C, 72.69; H, 9.15; N, 8.48. Found: C, 72.24; H, 9.80; N, 8.82.

4-(Cyclopent-1-enyl)-2-ethoxy-1,1,1,1-pentacarbonyl-4-(phenylamino)-1-tungsta-1,3-butadiene ((3*Z*)-10a), Pentacarbonyl[(3-ethoxy-3a,5,6,6a-tetrahydro-4H-pentalen-6a-ylidene)phenylamine-N]tungsten (*syn*-11a and *anti*-11a), and (3-Ethoxy-3a,5,6,6a-tetrahydro-4H-pentalen-6a-ylidene)phenylamine (12). A solution of aniline (47 mg, 0.5 mmol) in 1 mL of dry diethyl ether is added dropwise and slowly at 0 °C with stirring to pentacarbonyl[3-(cyclopent-1-enyl)-1-ethoxyprop-2-yn-1-ylidene]tungsten (236 mg, 0.50 mmol; **3a**) in 1 mL of dry diethyl ether. A color change from brown to red is observed at the point of equivalency after ca. 5 min. The solvent is removed immediately by evaporation to leave a red, thermolabile oil of compound (3*Z*)-10a (R_f = 0.7 in 10:1 pentane/diethyl ether). Compound (3*Z*)-10a generated by reaction of aniline (47 mg, 0.5 mmol) with **3a** (236 mg, 0.5 mmol) is rearranged at 50 °C and 4 h in 1 mL of toluene to give a 2:1 mixture of compounds *syn*-11a and *anti*-11a (255 mg, 89%, orange oil), which is separated by chromatography on silica gel to give *anti*-11a (R_f = 0.8 10:1 pentane/diethyl ether, yellow crystals, mp 136 °C) and *syn*-11a (R_f = 0.7 10:1 pentane/diethyl ether, orange crystals, mp 108 °C) and a small fraction of the colorless, very polar compound 12. Compound *syn*-11a rearranges to *anti*-11a in C_6D_6 at 50 °C. Compound 12 is generated under the influence of air in solutions both of *syn*-11a and *anti*-11a.

(3*Z*)-10a. ^1H NMR (C_6D_6 at 283 K, freshly prepared sample): δ 10.12 (1 H, s broad, NH), 7.01, 6.92, and 6.75 (2:1:2 H; "t", "t", "d"; C₆H₅), 6.88 (1 H, s, 3-H), 6.08 (1 H, "s" broad, 2'-H), 4.45 (2 H, q, OCH₂), 1.96 and 1.46 (4:2 H, CH₂ each), 0.96 (3 H, t, OCH₂CH₃). ^{13}C NMR (C_6D_6 at 283 K): δ 275.0 (C_q, W=C), 204.7 and 199.6 (C_q each, *trans*- and *cis*-CO of W(CO)₅), 149.7 (C_q, i-C NPh), 139.0 and 138.8 (C_q each, C4 and C1'), 139.7 (CH, C2'), 129.7, 129.6, 126.3, 124.8, and 123.5 (CH each, 1:1:1:1; 2 m-C, p-C, and 2 o-C; Ph), 122.5 (CH, C2'), 94.0 (CH, C3), 77.0 (OCH₂), 33.8 and 33.4 (CH₂ each, C8 and C6), 24.0 (CH₂, C7), 14.9 (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2058.8 (5), 1968.8 (10), 1931.0 (100) [ν (C≡O)]. Anal. Calcd for $\text{C}_{21}\text{H}_{19}\text{NO}_6\text{W}$ (565.2): C, 44.62; H, 3.39; N, 2.48. Found: C, 45.01; H, 3.57; N, 2.57.

anti-11a. ^1H NMR (C_6D_6): δ 7.16 and 7.12 (1 H each, m each, m-H Ph), 6.90 (CH, m, p-H Ph), 6.87 and 6.72 (1 H each, o-H Ph), 4.48 (1 H, s, 2-H), 3.28 (1 H, m, 6a-H), 2.85 and 2.75 (1 H each, m each, diastereotopic OCH₂), 2.70 (1 H, m, 3a-H), 2.15 and 1.65 (1 H each, m each, diastereotopic 4-H₂), 2.00 and 1.41 (1 H each, m each, diastereotopic 5-H₂), 1.20 (2 H, m each, diastereotopic 6-H₂), 0.70 (3 H, t, OCH₂CH₃). ^{13}C NMR (C_6D_6): δ 204.4 and 199.7 (C_q each, *trans*- and *cis*-CO, W(CO)₅), 190.7 (C_q, C=N), 184.0 (C_q, =C=O), 158.5 (C_q, i-C NPh), 129.7 and 129.5 (CH each, m-C NPh), 125.7 and 121.4 (CH each, o-C NPh), 121.9 (CH, p-C NPh), 99.9 (CH, C2), 67.2 (OCH₂), 50.0 and 48.6 (CH each, C6a and C3a), 32.6 (CH₂, C4), 28.5

(CH₂, C6), 24.0 (CH₂, C5), 13.7 (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2067.4 (5), 1970.5 (10), 1927.9 (100), 1907.6 (30) [ν (C≡O)]; 1576.4 (20) [ν (C=N)]. MS (70 eV; m/e 184W (%)): 565 (10) [M⁺], 537 (10), 509 (80) [M⁺ - 2 CO], 481 (10) [M⁺ - 3 CO], 453 (40) [M⁺ - 4 CO], 425 (60) [M⁺ - 5 CO], 241 (100) [ligand]. Anal. Calcd for C₂₁H₁₉NO₆W (565.2): C, 44.62; H, 3.39; N, 2.48. Found: C, 44.79; H, 3.82; N, 2.70.

syn-11a. ¹H NMR (C₆D₆): δ 7.07 (2 H, m, m-H Ph), 6.84 (CH, m, p-H Ph), 6.82 and 6.52 (1 H each, o-H Ph), 5.92 (1 H, s, 2-H), 3.62 (2 H, m, diastereotopic OCH₂), 2.62 and 2.51 (1 H each, m each, 6a-H and 3a-H), 1.4-0.8 (6 H, m, 3 CH₂), 0.92 (3 H, t, OCH₂CH₃). ¹³C NMR (C₆D₆): δ 203.3 and 199.9 [C_q each, *trans*- and *cis*-CO, W(CO)₅], 189.8 (C_q, C=N), 184.6 (C_q, =C-O), 155.3 (C_q, i-C NPh), 129.8 and 129.4 (CH each, m-C NPh), 125.6 (CH, p-C NPh), 123.9 and 121.3 (CH each, o-C NPh), 105.7 (CH, C2), 68.0 (OCH₂), 50.0 and 45.7 (CH each, C₆a and C₃a), 32.6 (CH₂, C4), 28.7 (CH₂, C6), 26.0 (CH₂, C5), 13.8 (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2067.4 (5), 1970.1 (10), 1928.9 (100), 1907.1 (30) [ν (C=O)]; 1575.4 (20) [ν (C=N)]. MS (70 eV; m/e 184W (%)): 565 (20) [M⁺], 537 (10), 509 (95) [M⁺ - 2 CO], 481 (10) [M⁺ - 3 CO], 453 (40) [M⁺ - 4 CO], 425 (60) [M⁺ - 5 CO], 241 (100) [ligand]. Anal. Calcd for C₂₁H₁₉NO₆W (565.2): C, 44.62; H, 3.39; N, 2.48. Found: C, 44.63; H, 3.64; N, 2.64.

X-ray crystal structure analysis of compound **anti-11a**: formula C₂₁H₁₉NO₆W, M_r = 565.22, 0.3 × 0.2 × 0.2 mm, a = 9.801(4) Å, b = 10.423(3) Å, c = 11.903(3) Å, α = 97.39(2)°, β = 112.70(2)°, γ = 104.98(2)°, V = 1047.5(6) Å³, ρ_{calcd} = 1.792 g cm⁻³, μ = 55.50 cm⁻¹, empirical absorption correction via ψ scan data (0.799 ≤ C ≤ 0.999), Z = 2, triclinic, space group P1 (No. 2), λ = 0.710 73 Å, T = 223 K, $\omega/2\theta$ scans, 4424 reflections collected ($\pm h$, $\pm k$, $\pm l$), ($\sin \theta/\lambda$) = 0.62 Å⁻¹, 4215 independent and 3881 observed reflections [$I \geq 2\sigma(I)$], 263 refined parameters, R1 = 0.021, wR2 = 0.056, GOF 1.167, maximum (minimum) residual electron density 0.84 (-1.17) e Å⁻³, hydrogens calculated and riding.¹³

12. ¹H NMR (C₆D₆): δ 7.29 (2 H, m, m-H Ph), 7.12 (2 H, m, o-H Ph), 6.99 (CH, m, p-H Ph), 5.18 (1 H, s, 3-H), 3.18 (1 H, m, 5-H), 3.05 and 2.85 (1 H each, m each, diastereotopic OCH₂), 2.30 (1 H, m, 1-H), 1.7-1.2 (6 H, m, 3 CH₂), 0.82 (3 H, t, OCH₂CH₃). ¹³C NMR (C₆D₆): δ 181.5 (C_q, C=N), 177.6 (C_q, =C-O), 154.5 (C_q, i-C NPh), 129.2 (CH, m-C NPh), 122.1 (CH, p-C NPh), 121.3 (CH, o-C NPh), 97.4 (CH, C3), 66.3 (OCH₂), 48.7 and 46.6 (CH each, C5 and C1), 32.3 (CH₂, C8), 29.4 (CH₂, C6), 24.2 (CH₂, C7), 14.0 (OCH₂CH₃). IR (diffuse reflection; cm⁻¹ (%)): 1645.4 [ν (C=N)]. MS (70 eV; m/e (%)): 241 (100) [M⁺], 213 (40), 185 (30), 144 (30). Anal. Calcd for C₂₁H₁₉NO₆W (565.2): C, 44.62; H, 3.39; N, 2.48. Found: C, 44.79; H, 3.82; N, 2.70.

4-(Cyclopent-1-enyl)-2-ethoxy-1,1,1,1-pentacarbonyl-4-(phenylamino)-1-chroma-1,3-butadiene ((3Z)-10b) and Pentacarbonyl[3-ethoxy-3a,5,6,6a-tetrahydro-4H-pentalen-6a-ylidene]phenylamine-N]chromium (syn-11b** and **anti-11b**).**

A solution of aniline (47 mg, 0.5 mmol) is reacted with pentacarbonyl[3-(cyclopent-1-enyl)-1-ethoxyprop-2-yn-1-ylidene]chromium (170 mg, 0.5 mmol; **3b**) as described above to give compound (3Z)-**10a** (R_f = 0.7 in 10:1 pentane/diethyl ether; red, thermolabile oil). Compound (3Z)-**10b** generated by reaction of aniline (47 mg, 0.5 mmol) with **3b** (170 mg, 0.5 mmol) as described above is rearranged at 50 °C and 4 h in 1 mL of toluene to give a 1:1 mixture of compounds **syn-11b** and **anti-11b** (255 mg, 89%, orange oil), which are separated by chromatography on silica gel to give **anti-11b** (R_f = 0.8 10:1 pentane/diethyl ether, yellow crystals, mp 99 °C) and **syn-11b** (R_f = 0.7 10:1 pentane/diethyl ether) and a fraction of the colorless, very polar compound **12** (vide supra). Compound **syn-11b** rearranges to **anti-11b** in C₆D₆ at 50 °C. Compound **12** is generated under the influence of air from solutions both of **syn-11b** and **anti-11b**.

(3Z)-10b. ¹H NMR (C₆D₆ at 303 K, freshly prepared sample): δ 10.00 (1 H, s broad, NH), 6.90, 6.82, and 6.71 (2:

1:2 H, C₆H₅), 6.68 (1 H, s, 3-H), 6.08 (1 H, "s" broad, 2'-H), 4.62 (2 H, q, OCH₂), 1.96 and 1.42 (4:2 H, CH₂ each), 0.90 (3 H, t, OCH₂CH₃). ¹³C NMR (C₆D₆ at 303 K): δ 298.8 (C_q, Cr=C), 224.4 and 219.2 [C_q each, *trans*- and *cis*-CO of Cr(CO)₅], 145.7 (C_q, i-C NPh), 140.0 and 138.8 (C_q each, C4 and C1'), 139.5 (CH, C2'), 129.7, 129.4, 126.9, 125.0, and 122.5 (CH each, 1:1:1:1:1; 2 m-C, p-C and 2 o-C; NPh), 122.5 (CH, C2'), 94.2 (CH, broad, C3), 74.4 (OCH₂), 33.8 and 33.3 (CH₂ each, C8 and C6), 24.0 (CH₂, C7), 15.0 (OCH₂CH₃).

anti-11b. ¹H NMR (C₆D₆): δ 7.15 and 7.10 (1 H each, m each, m-H Ph), 6.90 (CH, m, p-H Ph), 6.85 and 6.73 (1 H each, o-H Ph), 4.47 (1 H, s, 2-H), 3.30 (1 H, m, 6a-H), 2.83 and 2.70 (1 H each, m each, diastereotopic OCH₂), 2.74 (1 H, m, 3a-H), 2.10 and 1.62 (1 H each, m each, diastereotopic 4-H₂), 2.03 and 1.41 (1 H each, m each, diastereotopic 5-H₂), 1.23 (2 H, m each, diastereotopic 6-H₂), 0.68 (3 H, t, OCH₂CH₃). ¹³C NMR (C₆D₆): δ 222.6 and 215.5 [C_q each, *trans*- and *cis*-CO, W(CO)₅], 190.6 (C_q, C=N), 182.6 (C_q, =C-O), 159.0 (C_q, i-C NPh), 129.9 and 129.6 (CH each, m-C NPh), 125.1 and 121.5 (CH each, o-C NPh), 125.0 (CH, p-C NPh), 100.1 (CH, C2), 67.0 (OCH₂), 48.9 and 48.4 (CH each, C6a and C3a), 33.0 (CH₂, C4), 28.5 (CH₂, C6), 24.0 (CH₂, C5), 13.7 (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2063.0 (5), 1975.1 (10), 1933.1 (100), 1908.9 (30) [ν (C=O)]; 1574.1 (20) [ν (C=N)]. MS (70 eV; m/e (%)): 433 (5) [M⁺], 377 (5) [M⁺ - 2 CO], 321 (5) [M⁺ - 4 CO], 293 (80) [M⁺ - 5 CO], 241 (100) [ligand], 99 (80). Anal. Calcd for C₂₁H₁₉CrNO₆ (433.4): C, 58.20; H, 4.42; N, 3.23. Found: C, 58.64; H, 4.90; N, 3.52.

syn-11b. ¹H NMR (C₆D₆): δ 7.09 (2 H, m, m-H Ph), 6.86 (CH, m, p-H Ph), 6.79 and 6.51 (1 H each, o-H Ph), 5.89 (1 H, s, 2-H), 3.69 (2 H, m, diastereotopic OCH₂), 2.63 and 2.50 (1 H each, m each, 3a-H and 6a-H), 1.4-0.8 (6 H, m, 3 CH₂), 1.00 (3 H, t, OCH₂CH₃). ¹³C NMR (C₆D₆): δ 222.1 and 215.5 [C_q each, *trans*- and *cis*-CO, W(CO)₅], 189.6 (C_q, C=N), 184.2 (C_q, =C-O), 155.7 (C_q, i-C NPh), 129.2 and 128.8 (CH each, m-C NPh), 125.1 (CH, p-C NPh), 123.8 and 121.6 (CH each, o-C NPh), 103.2 (CH, C2), 67.8 (OCH₂), 48.9 and 46.7 (CH each, C6a and C3a), 31.5 (CH₂, C4), 28.8 (CH₂, C6), 26.0 (CH₂, C5), 13.9 (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2063.4 (5), 1975.1 (10), 1932.9 (100), 1908.3 (30) [ν (C=O)]; 1579.0 (20) [ν (C=N)]. MS (70 eV; m/e (%)): 433 (10) [M⁺], 377 (5) [M⁺ - 2 CO], 321 (5) [M⁺ - 4 CO], 293 (60) [M⁺ - 5 CO], 241 (80) [ligand], 99 (100). Anal. Calcd for C₂₁H₁₉CrNO₆ (433.4): C, 58.20; H, 4.42; N, 3.23. Found: C, 58.30; H, 5.07; N, 3.41.

Pentacarbonyl[4-ethoxy-6-(di-tert-butylphosphanyl)-1,2,3,3a-tetrahydropentalene-P]tungsten (anti-14a), Pentacarbonyl[4-ethoxy-6-(di-tert-butylphosphanyl)-1,2,3,6a-tetrahydropentalene-P]tungsten(anti-15a), and Pentacarbonyl[3-(di-tert-butylphosphanyl)-3a,5,6,6a-tetrahydro-4H-pentalen-1-one-P]tungsten (anti-17a). To pentacarbonyl-[3-(cyclopent-1-enyl)-1-ethoxyprop-2-yn-1-ylidene]tungsten (236 mg, 0.5 mmol; **3a**) in 1 mL of pentane is added di-tert-butylphosphine (73 mg, 0.5 mmol; **13a**) in 2 mL of pentane dropwise at 0 °C with stirring in a 5 mL screw-top vessel. After the color change to yellow is observed, indicating that the point of equivalency is achieved, the solution separated by fast (!) chromatography on silica gel to give compound **anti-14a** (R_f = 0.6 in 50:1 pentane/diethyl ether, yellow crystals, mp 90 °C), compound **anti-15a** (R_f = 0.5 in 50:1 pentane/diethyl ether, yellow crystals, mp 76 °C), and compound **anti-17a** (R_f = 0.5 in diethyl ether, yellow crystals, mp 127 °C). The overall yield of compounds **anti-14a** + **anti-15a** + **anti-17a** corresponds to ca. 80%. Since **anti-14a** readily undergoes thermal rearrangement to **anti-15a** and also is hydrolyzed on silica gel to give **anti-17a**, the relative yields depend very much on the details of the preparation.

anti-14a. ¹H NMR (C₆D₆): δ 5.68 [1 H, d, ³J(P,H) = 8 Hz, 5-H], 3.65 (2 H, m, diastereotopic OCH₂), 3.36 (1 H, m, 3a-H), 2.38 (2 H, m, diastereotopic 1-H₂), 1.90 and 1.60 (2 H each, m each, 2-H₂ and 3-H₂), 1.31 and 1.25 [3 H each, d each, ³J(P,H) = 13 Hz each, diastereotopic Pt-Bu₂], 1.10 (3 H, t, OCH₂CH₃).

¹³C NMR (C_6D_6): δ 200.2 [C_q , 4 C, $^2J(P,C) = 7$ Hz, *cis*-CO, (CO_5W), 199.2 [C_q , $^2J(P,C) = 24$ Hz, *trans*-CO, (CO_5W)], 164.5 [C_q , $^3J(P,C) = 9$ Hz, C4], 153.5 [C_q , $^2J(P,C) = 0$ Hz, C6a], 149.9 [C_q , $^1J(P,C) = 17$ Hz, C6], 109.2 [CH, $^2J(P,C) = 17$ Hz, C5], 65.4 (OCH₂), 60.4 [CH, $^3J(P,C) = 6$ Hz, C3a], 37.9 and 37.4 [C_q each, $^1J(P,C) = 13$ Hz each, diastereotopic PCMe₃], 30.6 (CH₂, C1), 29.2 and 26.3 (CH₂ each, C2 and C3), 31.3 and 31.0 [CH₃ each, $^2J(P,C) = 7$ Hz each, diastereotopic CM₃], 14.5 (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2066.1 (20), 1970.0 (5), 1938.5 (90), 1928.0 (100) [$\nu(C\equiv O)$]. MS (70 eV; ^{184}W , m/e (%)): 618 (20) [M⁺], 590 (5), 562 (40), 534 (20), 506 (60), 478 (10) [M⁺ - 5 CO], 417 (70), 294 (20) [ligand], 237 (60), 57 (100). Anal. Calcd for $C_{23}H_{31}O_6PW$ (618.3): C, 44.68; H, 5.05. Found: C, 44.61; H, 4.97.

anti-15a. ¹H NMR (C_6D_6): δ 7.40 [1 H, d, $^3J(P,H) = 8$ Hz, 5-H], 3.85 (2 H, m, diastereotopic OCH₂), 3.38 (1 H, m, 6a-H), 2.20 (2 H, m, diastereotopic 3-H₂), 2.00 and 1.85 (2 H each, m each, 2-H₂ and 1-H₂), 1.28 and 1.05 [3 H each, d each, $^3J(P,H) = 14$ Hz each, diastereotopic P-*t*-Bu₂], 1.07 (3 H, t, OCH₂CH₃). ¹³C NMR (C_6D_6): δ 199.8 [C_q , 4 C, $^2J(P,C) = 7$ Hz, *cis*-CO, (CO_5W), 198.9 [C_q , $^2J(P,C) = 22$ Hz, *trans*-CO, (CO_5W)], 150.8 [C_q , $^3J(P,C) = 15$ Hz, C4], 150.0 [CH, $^2J(P,C) = 19$ Hz, C5], 138.9 [C_q , $^1J(P,C) = 20$ Hz, C6], 132.0 [C_q , $^3J(P,C) = 0$ Hz, C3a], 65.0 (OCH₂), 61.9 (CH, C6a), 38.9 and 36.5 [C_q each, $^1J(P,C) = 13$ and 15 Hz, respectively, diastereotopic PCMe₃], 32.7 (CH₂, C3), 31.0 and 22.5 (CH₂ each, C2 and C1), 30.8 and 30.4 [CH₃ each, $^2J(P,C) = 6$ Hz each, diastereotopic CM₃], 15.3 (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2067.1 (20), 1970.3 (5), 1935.5 (100) [$\nu(C\equiv O)$]. MS (70 eV; ^{184}W , m/e (%)): 618 (10) [M⁺], 590 (5), 534 (30), 506 (20), 478 (30) [M⁺ - 5 CO], 154 (60), 57 (100). Anal. Calcd for $C_{23}H_{31}O_6PW$ (618.3): C, 44.68; H, 5.05. Found: C, 44.31; H, 5.07.

anti-17a. ¹H NMR (C_6D_6): δ 6.63 [1 H, d, $^3J(P,H) = 6$ Hz, 2-H], 3.30 (1 H, m, 6a-H), 2.60 (1 H, m, 3a-H), 1.95 and 1.70 (1 H each, m each, diastereotopic 4-H₂), 1.30–1.20 (4 H, m, 5-H₂ and 6-H₂), 1.08 and 1.01 [3 H each, d each, $^3J(P,H) = 14$ Hz each, diastereotopic P-*t*-Bu₂]. ¹³C NMR (C_6D_6): δ 208.5 (C_q , $^3J(P,C) = 11$ Hz, C=O], 199.2 [C_q , 4 C, $^2J(P,C) = 7$ Hz, *cis*-CO, (CO_5W), 198.0 [C_q , $^2J(P,C) = 22$ Hz, *trans*-CO, (CO_5W)], 174.2 (C_q , $^1J = 4$ Hz, C3), 143.5 [CH, $^2J(P,C) = 6$ Hz, C2], 54.6 (CH, C6a), 53.0 (CH, $^2J = 4$ Hz, C3a), 38.3 and 37.9 [C_q each, $^1J(P,C) = 13$ and 11 Hz, respectively, diastereotopic PCMe₃], 34.5 (CH₂, C4), 31.3 and 31.0 [CH₃ each, $^2J(P,C) = 5$ Hz each, diastereotopic CM₃], 27.2 and 27.1 (CH₂ each, C5 and C6). IR (hexane; cm⁻¹ (%)): 2068.4 (20), 1973.2 (5), 1935.9 (100) [$\nu(C\equiv O)$]; 1710.5 [$\nu(C=O)$]. MS (70 eV; ^{184}W , m/e (%)): 590 (10) [M⁺], 562 (5), 534 (30), 506 (20), 476 (30), 450 (30) [M⁺ - 5 CO], 421 (30), 391 (20), 266 (10) [ligand], 210 (10), 154 (60), 57 (100). Anal. Calcd for $C_{21}H_{27}O_6PW$ (590.3): C, 42.73; H, 4.61. Found: C, 42.66; H, 4.63.

X-ray crystal structure analysis of compound **anti-17a**: formula $C_{21}H_{27}O_6PW$, $M_r = 590.25$, $0.7 \times 0.5 \times 0.4$ mm, $a = 14.810(1)$ Å, $b = 10.653(2)$ Å, $c = 15.583(1)$ Å, $\beta = 110.19(1)$ °, $V = 2307.5(5)$ Å³, $\rho_{calcd} = 1.699$ g cm⁻³, $\mu = 51.07$ cm⁻¹, empirical absorption correction via ψ scan data ($0.758 \leq C \leq 0.999$), $Z = 4$, monoclinic, space group $P2_1/n$ (No. 14), $\lambda = 0.710$ 73 Å, $T = 223$ K, $\omega/2\theta$ scans, 4854 reflections collected ($\pm h, -k, -l$), ($\sin \theta/\lambda = 0.62$ Å⁻¹, 4680 independent and 4173 observed reflections [$I \geq 2\sigma(I)$], 268 refined parameters, R1 = 0.030, wR2 = 0.081, GOF 1.094, maximum (minimum) residual electron density 1.89 (-1.47) e Å⁻³, refined with isotropic thermal parameters and with restraints, hydrogens calculated and riding.¹³

Pentacarbonyl[4-ethoxy-6-(dicyclohexylphosphanyl)-1,2,3,3a-tetrahydropentalene-*P*]tungsten (anti-14b**), Pentacarbonyl[4-ethoxy-6-(dicyclohexylphosphanyl)-1,2,3,5-tetrahydropentalene-*P*]tungsten (**anti-16b**), and Pentacarbonyl[3-(dicyclohexylphosphanyl)-3a,5,6,6a-tetrahydro-4*H*-pentalen-1-one-*P*]tungsten (**anti-17b**).** Pentacarbonyl[3-(cyclopentadiene-annulated pentalen-1-one)-*P*]tungsten (**anti-14b**) was prepared by the method described previously.¹⁴ Compound **anti-14b** (236 mg, 0.5 mmol) was reacted with dicyclohexylphosphine (99 mg, 0.5 mmol; **13b**) as described above to give compound **anti-14b** (202 mg, 30%, $R_f = 0.5$ in 50:1 pentane/diethyl ether), compound **anti-15b** (45 mg, 7%, $R_f = 0.6$ in 50:1 pentane/diethyl ether), compound **anti-16b** (240 mg, 36%, $R_f = 0.6$ in 50:1 pentane/diethyl ether, mp 151 °C), and compound **anti-17b** (140 mg, 22%, $R_f = 0.3$ in 4:1 pentane/dichloromethane, mp 163 °C). Since **anti-14b** readily undergoes thermal rearrangement to **anti-15b** and **anti-16b** and is readily hydrolyzed on silica gel to give **anti-17b**, the relative yields depend very much on the details of preparation.

anti-14b. ¹H NMR (C_6D_6): δ 5.52 [1 H, d, $^3J(P,H) = 2$ Hz, 5-H], 3.65 (2 H, m, diastereotopic OCH₂), 3.42 (1 H, m, 1-H), 2.30 (2 H, m, diastereotopic 1-H₂), 2.10–1.10 (26 H, m; 2-H₂, 3-H₂, and 2 Cy), 1.10 (3 H, t, OCH₂CH₃). ¹³C NMR (C_6D_6): δ 199.3 [C_q , 4 C, $^2J(P,C) = 6$ Hz, *cis*-CO, (CO_5W), 199.5 [C_q , $^2J(P,C) = 22$ Hz, *trans*-CO, (CO_5W)], 165.9 [C_q , $^3J(P,C) = 9$ Hz, C4], 153.6 [C_q , $^2J(P,C) = 0$ Hz, C6a], 149.5 [C_q , $^1J(P,C) = 15$ Hz, C6], 106.2 [CH, $^2J(P,C) = 26$ Hz, C5], 65.4 (OCH₂), 60.4 [CH, $^3J(P,C) = 7$ Hz, C3a], 38.5 and 36.5 [CH each, $^1J(P,C) = 24$ Hz each, diastereotopic PC₂H], 30.8 (CH₂, C1), 29.6 and 25.8 (CH₂ each, C2 and C3), 29.3–26.0 (10 CH₂, diastereotopic PCy₂), 14.3 (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2066.7 (20), 1969.5 (5), 1937.4 (100), 1928.0 (70) [$\nu(C\equiv O)$]. MS (70 eV; ^{184}W , m/e (%)): 670 (20) [M⁺], 642 (25), 614 (40), 586 (60), 558 (40), 530 (30) [M⁺ - 5 CO], 55 (100). Anal. Calcd for $C_{27}H_{35}O_6PW$ (670.4): C, 48.37; H, 5.26. Found: C, 48.60; H, 5.36.

anti-15b. ¹H NMR (C_6D_6): δ 7.230 [1 H, d, $^3J(P,H) = 8$ Hz, 5-H], 3.90 (2 H, m, diastereotopic OCH₂), 3.30 (1 H, m, 6a-H), 2.25 (2 H, m, diastereotopic 1-H₂), 2.20–1.10 (26 H, m; 2-H₂, 3-H₂ and 2 Cy), 1.07 (3 H, t, OCH₂CH₃). ¹³C NMR (C_6D_6): δ 199.6 [C_q , 4 C, *cis*-CO, (CO_5W), 198.0 [C_q , *trans*-CO, (CO_5W)], 151.2 (C_q , C4), 150.2 (CH, C5), 137.0 (C_q , C6), 132.2 (C_q , C3a), 65.2 (OCH₂), 61.9 (CH, C6a), 38.5 and 36.5 [CH each, diastereotopic PC₂H], 32.7 (CH₂, C3); 31.0 and 22.8 (CH₂ each, C2 and C1), 29.4–25.9 (10 CH₂, diastereotopic PCy₂), 15.2 (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2067.0 (20), 1972.3 (5), 1935.2 (100) [$\nu(C\equiv O)$].

anti-16b. ¹H NMR (C_6D_6): δ 3.78 [2 H, m, 5-H₂], 3.70 (2 H, m, diastereotopic OCH₂), 2.32 (2 H, m, diastereotopic 3-H₂), 2.19 (2 H, m, 2-H₂), 2.10–1.10 (24 H, m, 1-H₂ and 2 Cy), 1.04 (3 H, t, OCH₂CH₃). ¹³C NMR (C_6D_6): δ 199.4 [C_q , 4 C, $^2J(P,C) = 8$ Hz, *cis*-CO, (CO_5W), 199.3 [C_q , $^2J(P,C) = 21$ Hz, *trans*-CO, (CO_5W)], 166.5 [C_q , $^3J(P,C) = 0$ Hz, C4], 158.9 [C_q , $^1J(P,C) = 9$ Hz, C6], 149.5 [C_q , $^2J(P,C) = 6$ Hz, C6a], 106.3 [CH, $^3J(P,C) = 43$ Hz, C3a], 65.9 (OCH₂), 53.4 (CH₂, $^2J = 20$ Hz, C5), 37.5 [2 PC₂H, $^1J(P,C) = 26$ Hz], 30.6 (CH₂, C1), 29.0 (CH₂, C2), 28.8 and 28.4 (CH₂ each, diastereotopic PC₂HCH₂CH₂), 27.3 and 27.0 (CH₂ each, $^3J = 13$ and 11 Hz, diastereotopic PC₂HCH₂CH₂), 26.3 (2 CH₂, PC₂HCH₂CH₂CH₂), 24.4 (CH₂, C2), 15.2 (OCH₂CH₃). IR (hexane; cm⁻¹ (%)): 2065.1 (20), 1967.5 (5), 1932.6 (100) [$\nu(C\equiv O)$]. Anal. Calcd for $C_{27}H_{35}O_6PW$ (670.4): C, 48.37; H, 5.26. Found: C, 48.52 H, 5.42.

X-ray crystal structure analysis of compound **anti-16b**: formula $C_{27}H_{35}O_6PW$, $M_r = 670.37$, $0.4 \times 0.3 \times 0.2$ mm, $a = 14.206(2)$ Å, $b = 11.564(2)$ Å, $c = 18.103(3)$ Å, $\beta = 112.72(1)$ °, $V = 2743.2(8)$ Å³, $\rho_{calcd} = 1.623$ g cm⁻³, $\mu = 43.07$ cm⁻¹, empirical absorption correction via ψ scan data ($0.933 \leq C \leq 0.999$), $Z = 4$, monoclinic, space group $P2_1/n$ (No. 14), $\lambda = 0.710$ 73 Å, $T = 223$ K, $\omega/2\theta$ scans, 5735 reflections collected ($\pm h, -k, -l$), ($\sin \theta/\lambda = 0.62$ Å⁻¹, 5558 independent and 4039 observed reflections [$I \geq 2\sigma(I)$], 317 refined parameters, R1 = 0.027, wR2 = 0.047, GOF 1.008, maximum (minimum) residual electron density 0.69 (-0.49) e Å⁻³, refined with isotropic thermal parameters and with restraints, hydrogens calculated and riding.¹³

anti-17b. ¹H NMR (C_6D_6): δ 6.30 [1 H, d, $^3J(P,H) = 6$ Hz, 2-H], 3.25 (1 H, m, 6a-H), 2.55 (1 H, m, 3a-H), 1.95–1.20 (27 H, m, 1-H₂–3-H₂, and 2 × CH₂ cyclohexanyl). ¹³C NMR (C_6D_6): δ 208.4 [C_q , $^3J(P,C) = 11$ Hz, C=O], 198.2 [C_q , 4 C,

$^2J(P,C) = 7$ Hz, *cis*-CO, (CO)₅W], 198.5 [C_q, $^2J(P,C) = 22$ Hz, *trans*-CO, (CO)₅W], 173.0 [C_q, $^1J(P,C) = 16$ Hz, C3], 141.5 [CH, $^2J(P,C) = 5$ Hz, C2], 53.2 (CH, C6a), 51.3 [CH, $^2J(P,C) = 8$ Hz, C3a], 38.7 and 38.0 [CH each, $^1J(P,C) = 22$ and 21 Hz, respectively, diastereotopic PCH], 32.3 (CH₂, C4), 29.5 and 29.0 [CH₂ each, $^2J(P,C) = 11$ and 4 Hz, respectively, diastereotopic PCH₂CH₂], 28.5 (CH₂, C5), 27.2 and 27.0 [CH₂ each, $^3J(P,C) = 9$ Hz each, PCHCH₂CH₂], 26.2 (2 CH₂, PCHCH₂CH₂CH₂), 26.0 (CH₂, C6). IR (hexane; cm⁻¹ (%)): 2068.7 (20), 1973.0 (5), 1937.1 (100) [ν (C=O)], 1709.9 [ν (C=O)]. MS (70 eV; ¹⁸⁴W, m/e (%)): 642 (10) [M⁺], 614 (5), 586 (30), 558 (20), 530 (30), 502 (30) [M⁺ - 5 CO], 283 (10) [ligand], 171 (50), 57 (100). Anal. Calcd for C₂₅H₃₁O₆PW (642.3): C, 46.75; H, 4.86. Found: C, 46.66; H, 4.92.

Acknowledgment. This work was supported by the Deutsche Forschungsgemeinschaft and the Fonds der Chemischen Industrie. We thank Barbara Hildmann for experimental assistance.

Supporting Information Available: Tables of positional and displacement parameters, bond distances and angles, and hydrogen coordinates for (3*E*)-**5a**, **6c**, *anti*-**11a**, *anti*-**16b**, and *anti*-**17a**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OM9810394